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CHAPTER 1 
INTRODUCTION 
Interactions that occur when organisms are infected at the same time by 
more than one type of virus are called interference. In general, this 
phenomenon manifests itself as tissue-immunity: tissue infected by one 
type of virus is resistant to infection by a second one. It has been 
assumed for a long time that a non-viral agent was responsible for this 
effect. It lasted until 1957 before this agent was discovered by 
Isaacs and Lindenmann, who called it interferon. Since 1957 a tremen-
dous effort has been invested in this agent with as main goal the cli-
nical application. Over the last 20 years more than 2000 papers on 
interferon have appeared. The main results of these studies are review-
ed in this chapter. 
The action of interferon is not virus-specific. In cells treated with 
interferon the replication of a wide spectrum of virusesisinhibited.In 
general, the activity of interferon is species-specific and restricted 
to the species in which it is induced. It has proven very difficult to 
purify interferon completely and this has only very recently been 
claimed for some interferons. So the physico-chemical characteristics 
of interferons have not yet been completely established. In Table 1 the 
general characteristics of interferons are listed. The major cause of 
the difficulties in purifying interferons is their tremendous biologi-
cal activity. Current estimates of the dilution of interferon still 
biologically active are as low as 10-15 M. If this is true, interferon 
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Table 1. General characteristics of interferons 
Glycoprotein 
Molecular weight 15,000 to 100,000 dalton 
Isoelectric point 6.5 to 7.5 
Activity: Unaffected in acid(pH 2.0) and alkaline(pH 11.0) solutions 
Species-specific 
Not virus-specific 
is 102 times more active than cobra venom, one of the most active bio-
logical agents. Because of the difficulties in purification, interferon 
has to be quantitated in a bioassay. Almost every laboratory has its 
own assay. A vast number of factors may influence the assay results. 
Therefore, international reference preparations are available of the 
most commonly studied types of interferon. 
Under normal conditions the gene for interferon production is sup-
pressed. When a cell is infected by a virus interferon production is 
probably triggered by daub l e-stranded RNA ( ds-RNA). It is generally 
held that both DNA and RNA viruses produce some ds-RNA during their 
replicative cycle. Also inactivated viruses will produce ds-RNA, pro-
vided their polymerase activity is retained. If the polymerase activity 
is inactivated, viruses will not induce interferon. Non-viral ds-RNA 
can also induce interferon. The most potent and widely used ds-RNA in-
ducer of interferon is the synthetic polyinosinic-polycytidylic acid 
(poly(rl).poly(rC)). 
i4idely used non-viral inducers are listed in Table 2. Some substances 
as pokeweed mitogen induce interferon in lymphoid cells only. These 
cells will then produce another type of interferon called type II 
interferon (or 'immune' interferon). So the type of inducer can in-
fluence the type of interferon produced. Lymphoid cells challenged with 
virus will produce the 'classical' interferon or type I interferon. 
Interferon does not inactivate viruses directly but its antiviral 
action is mediated by the cell. Interferon does not enter cells but 
interacts with a receptor on the cell surface. By this interaction an 
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TabZe 2. Non-viraZ inducers of interferons 
In vivo In vitro 
Polynucleotides + + 
Anionic polymers + 
Tilorone + + 
Acridine + 
Statolon + + 
Bacteria and endotoxins + 
Mitogens + +(type II interferon) 
intracellular protein is produced that exerts its antiviral effect on 
the molecular level. The level at which the viral replication is inhi-
bited is dependent on the virus-cell system studied. Inhibition of 
transscription, translation and viral maturation have been reported. 
The suggested mechanisms include changes in viral m-RNA, in cellular 
m-RNA ribosomes, induction of nucleases, changes in the t-RNA pool, 
changes in the initiation factors, etc. 
Interferon preparations not only exert antiviral but also other 
activities. These activities were generally considered to be caused by 
impurities, but recent studies with pure or almost pure preparations 
have shown that the interferon molecule itself is responsible for these 
•non-antiviral • activities. Cell division is delayed in interferon-
treated cells. Small doses prime cells for enhanced interferon produc-
tion after induction, while high doses inhibit production. Inter-
feron treatment enhances the expression of transplantation antigens 
on the cell surface. Other changes in cell surface properties, such 
as inhibition of thymidine transport, increase of binding of concana-
valin A and reduction of binding of thyroid-stimulating hormone and 
cholera toxin, are reported. Interferon can also enhance specialized 
cell functions, such as macrophage activity, natural killer (NK) cell 
activity and lymphocytic cytolysis of tumour cells. Interferon can 
modulate immune responses. It suppresses the delayed type hypersensi-
tivity in mice. When administered before or together with antigen, 
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antibody production will be inhibited. Given several days after an 
antigen it will enhance antibody production. 
When an organism is infected by a virus several host mechanisms are 
set to operate (Table 3). In general, the role of antibodies in viral 
Table 3. Antiviral defence mechanisms 
Inflammatory reactions 
Interferon 
Antibodies 
Cellular immunity 
Time needed 
for activation 
hours 
hours 
several days 
severa 1 days 
Function 
inhibition of 
viral replication 
inhibition of 
viral replication 
inhibition of 
viral spread 
inactivation and 
clearance of virus 
infections is restricted to the inhibition of viral spread. During 
first infections with a virus antibodies are formed too late to pre-
vent this transport. Some viruses spread without entering the extra-
cellular space and avoid exposing themselves to antibodies. When a 
virus is replicating, cellular immunity and interferon are the main 
defences. Interferon production starts within hours after infection. 
The cellular immune system needs days to be activated. Decrease of 
viral replication seems more related to the interferon production than 
to activation of the immune system. Antibodies to interferon injected 
in experimentally infected animals can change a harmless infection 
into a lethal one. So interferon plays an important part in the host 
defences against viral infections. However, interferon is only viro-
static and cannot clear viruses from the body like immune cells. The 
biological function of interferon seems to be to slow down an infection 
during the period necessary for activation of the immune system. 
Soon after the discovery of interferon it was shown that exogenous 
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interferon, applied locally or systemically, can control viral infec-
tions. In general, more interferon is needed to prevent than to cure 
viral infections. 
Interferon has been shown to be active against both virus-induced 
and non-virus-induced tumours in animals. Non-antiviral effects of 
interferon are supposed to play an important role in this antitumour 
effect, in particular macrophage activation and modulation of the 
immune system~ 
Use of interferon inducers is not yet feasible in man. Some inducers 
fail to induce interferon in man, others are toxic or antigenic. To 
evaluate its clinical usefulness, interferon has to be produced in 
vitro. The main sources for human interferon have been buffycoats in-
duced with Sendai virus and fibroblasts induced with poly(rl).poly(rC). 
The buffycoats yield human leucocyte interferon (HLI) and the fibro-
blasts human fibroblast interferon (HFI). HLI and HFI differ in phy-
sico-chemical, antigenic and biological characteristics. Most studies 
with human interferons in man are anecdotical. The dose of interferon 
and frequency of injections vary widely. l~e know of one study only in 
which the effect of systemically administered interferon was unequi-
vocally established (flerigan et aZ. 1978). In this study 500,000 units/ 
kg/day., started within a day after diagnosis of herpes zoster, were 
able to control the spread of the lesions. Also the results with 
topically applied interferon in herpes keratitis are convincing. All 
other studies, including those on the alleged beneficial effect of 
interferon i_n hepatitis B virus infections are uncontrolled, inconclu-
sive and involve just a few patients. There are also claims that inter-
feron has a beneficial effect in tumour patients. Again, these studies 
are not properly controlled. 
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Justi fi cation 
The main theme of this thesis is the clinical evaluation of interferon. 
From the biology of the interferon system and animal experiments it 
can be expected that exogenous interferon will exert its optimum effect 
when used to prevent acute infections or to modulate chronic infec-
tions. Therefore, we administered interferon to patients with chronic 
hepatitis B virus infection (chapter 5) and to renal transplant reci-
pients, in whom viral infections occur frequently in the first months 
after transplantation (chapter 6). 
The other studies in this thesis are directly related to the pro-
blems we met in the clinical studies. We wanted to study interferon in 
an animal renal transplantation model. For us the most obvious choice 
was the rat. However, little was known about the production and cha-
racterization of rat interferon. Chapter 2 describes our experiences 
with rat interferon. 
While we were well underway with the study in renal transplant reci-
pients, we were contacted by Martin Hirsch, who was conducting a 
similar trial in Boston. Some of his patients receiving 3 x 106 U HLI 
every other day showed severe bone marrow depression. We had no such 
problem in our trial, but we used another type of interferon: HFI. 
For this reason we started a study on the t'oxicity of interferons for 
bone marrow in vitro. The results are presented in the first part of 
chapter 4. We extended this study to a more fundamental approach of 
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growth inhibition. In the second part of chapter 4 we present a simple 
method to measure growth inhibition of cells in monolayer and some 
results with this method. 
Several possibilities arose to explain the negative results of the 
renal transplant trial, e.g. dosage, differential effects of HLI and 
HFI, and efficacy of interferon under circumstances of immunosuppres-
sion. We decided to study these problems in a monkey model. In the 
first part of chapter 7 we report our experiences with human interfercn 
preparations in vaccinia virus infected rhesus monkeys. During this 
study we found that human interferon was able to protect monkeys in 
vivo against vaccinia virus, while the same virus was insensitive to 
interferon in vitro. These results are presented in the second part of 
chapter 7. 
During the study of the in vitro sensitivity of viruses, we found 
that the effect of interferon was dependent on the amount of virus by 
which the cell cultures were infected. In chapter 2 the results are 
presented of an extensive study on the influence of multiplicity of 
infection on the antiviral effect of interferon in different cell-
virus systems. 
In this thesis the results of our studies have been arranged in such 
a way that the basic aspects of the interferon system, such as produc-
tion, characteristics, antiviral and non-antiviral activities precede 
the clinical studies. Thereafter the experiments in rhesus monkeys are 
presented because they elucidate some of the problems that arose during 
the studies in man. 
The clinical and basic studies have largely influenced each other. 
Therefore, we decided to present them in one thesis. We both feel 
responsible for the complete contents, although we have of course 
contributed from a different background. The greater part of this 
thesis has already been published in a number of publications (see 
page 7 ) . Authorship and order of authors indicate the extent to which 
each of us has contributed to the various studies. 
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IN VITRO STUDIES 
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CHAPTER 2 
PRODUCTION AND INITIAL CHARACTERIZATION OF RAT INTERFERON 
The purpose of this study was to develop the technology for the produc-
tion of rat interferon for in vivo studies. 
This study was achieved by cooperation of the Departments of Virology 
and Internal Medicine, Erasmus University Rotterdam. 
This chapter is based on: 
~Production and initial characterization of rat interferon' by 
H.Schellekens, G.A. de Wilde & W.Weimar, published in Journal of 
General Virology 46, 1980, 243-247. 
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Introduction 
Few and partly conflicting studies have been published on rat inter-
feron. Differences exist between reports on the physico-chemical pro-
perties and the activity of rat interferon in cells of other species 
(Biernacka & Lobodzinska, 1973; Lobodzinska et al. 1973; Illinger et 
aZ. 1976). Interesting is the reported antiviral activity of human 
interferons in rat cells and the ability of human interferon to inhi-
bit rat interferon activity (Duc-Goiran et aZ. 1971; Chany, 1976). 
However, all these studies have been performed with rather impure 
interferon preparations. This study was designed to produce rat inter-
feron of high activity for in vivo studies and to compare some of its 
physico-chemical and biological activities with other interferons. 
i4aterial and Methods 
Viruses 
The origin, propagation, and titration of herpes hominis type I, 
vaccinia, and vesicular stomatitis virus (VSV) are described in chap-
ter 3. Newcastle disease virus (NOV), Komarow strain, was grown in the 
allantoic fluid of 10-day-old chicken embryos. The titre of this virus 
was expressed in plaque forming units (PFU), established in primary 
chicken embryo cell cultures. 
CeZZs 
Mouse L929 cells were originally obtained from Flow Laboratories (Irvine, Scotland). Chicken embryo cells were prepared by mincing and 
trypsinizing 10-day-old chicken embryos. Rat embryo cells (REC) were 
prepared by mincing and trypsinizing approximately 15-day-old embryos 
of WAG/Rij rats. The first passage of these cells was pooled and 
stored in liquid nitrogen using dimethylsulphoxide (DMSO) as a cryo-
protective agent. REC used in these experiments were a subcultivation 
of the first passage. Normally, REC could be subcultivated up to the 
30th passage. After the 40th passage we designated these cells Ratec 
cells. This Ratec cell line has now undergone more than 100 passages 
in our laboratory without degeneration. 
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XC cells (derived from a Rous sarcoma virus-induced rat tumour) and 
RR1022 cells (from a Schmidt-Ruppin sarcoma in a Rattus norvegicus) 
were both obtained from the American Type Culture Collection. Cells 
derived from a· radiation-induced rat skin carcinoma (RSC cells), cells 
from rat urethral carcinomas (RUC cells), cells from a spontaneous rat 
rhabdomyosarcoma (RM cells) and cells from a rat osteosarcoma (ROS cells) 
were donated by Dr.G.W.Barendsen (Radiobiological Institute TNO, 
Rijswijk, The Netherlands). WIRA cells were donated by Dr.l.Gresser 
(Institut de Recherches Scientifiques sur le Cancer, Villejuif, 
France). Rous sarcoma virus-transformed human cells (RSb cells) were 
donated by Dr.T.Kuwata (Chiba University, Chiba, Japan). 
All cells were routinely propagated in Brockway prescription bottles, 
in Dulbecco's modification of Eagle's minimal essential medium (DMEM), 
supplemented with 10% foetal calf serum (FCS) and antibiotics. When 
cells were grown in roller bottles, DMEM was supplemented with a 
buffer solution. This 100 x concentrated buffer solution (pH 7.2) con-
sisted of 0.75 M-N-2-hydroxyethylpiperazine-N'-2-ethane sulphonic acid 
(HEPES), 0.5 M-N-tris-(hydroxymethyl)methyl-2-aminoethane sulphonic 
acid (TES) and 0.5 M-morpholinopropane sulphonic acid (MOPS). 
Interferons 
Mouse interferon (M!F) was induced with NOV in L929 cells. The inter-
feron preparation used had an activity of 106 units/mg protein. Hll 
was a kind gift from Dr. K. Cante 11 (Central Public He a 1 th Laboratory, 
Helsinki, Finland) and was prepared as described before (Cantell,1970). 
The activity was 105· 9 unitsjmg protein. HFI was prepared as described 
before (Billiau et aZ. 1973), and was obtained by the courtesy of 
Dr.A.Billiau (Rega Institute, University of Leuven, Leuven, Belgium). 
HFI had an activity of 106 units/mg protein. 
To produce rat interferon (RIF) 2 x 107 Ratec cells in 100 ml DM8~ 
plus 10% FCS were grown in 1.5 1 roller bottles rotating at 0.5 rev/ 
min. Usually within 4 days confluency was reached and the cells were 
refed with 100 ml DMEM plus 10% newborn calf serum (NCS). The next day 
the culture medium was discarded and the cells were challenged with 
NOV at a multiplicity of infection of 30 to 50 PFU/cell for 90 min. 
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After challenge the cells were washed twice with phosphate buffered 
saline (PBS) and 50 ml OMEM without serum added. After 24 h the medium 
was harvested and centrifugated for 2 h at 150,000 g to remove the 
bulk of NOV. The remaining NOV was either inactivated by pH 2.0 treat-
ment for 5 days, or by adding perchloric acid to 0.15 M for 30 min. 
Perchloric acid treatment did not result in loss of antiviral activity. 
After adjusting the pH to 6.0 with 5.0 ~1-NaOH, the preparation was 
stored frozen at -20° C and designated 'crude interferon'. No replica-
tion of residual live NOV could be demonstrated after inoculation of 
the preparations in chicken embryos. 
Interferon aeeay 
Cells were grown in, microtitre plates at a concentration of 2 x 104 
cells per well in OMEM supplemented with 10% FCS. Hhen a monolayer was 
formed, the supernatant was removed and the preparation to be tested 
added in twofo 1 d di 1 uti ons in m1EM with 1% FCS. After overnight i ncuba-
tion the supernatant was again removed, the cells were washed with PBS 
(Oulbecco's modification) and infected with VSV at a multiplicity of 
infectio" 10 tissue culture infective dose (50%) (TCJo50 ) per well. 
When the untreated infected control showed > 90% cytopathogenic effect, 
the incubation was terminated and the cells were stained with crystal 
violet. The interferon activity was expressed as the reciprocal of the 
maximum dilution protecting 50% of the cells. This 50% endpoint was 
either estimated visually or established by the dye elution method of 
Armstrong (Armstrong, 1971). 
In every assay a laboratory standard was included to correct for 
variables between the different tests. One of the first rat interferon 
preparations produced in rat embryo cells challenged with NOV was dilu-
ted in OMEM supplemented with 10% FCS and stored in small ampoules at 
-70° C to serve as laboratory standard. The mean result of the first 10 
tests of the antiviral activity of this standard was 96 units. This 
preparation was therefore considered to contain 100 laboratory refe-
rence units of RIF and all RIF activities in this study were titrated 
against this standard. This standard preparation has been tested until 
now on 28 different occasions. The results of all these tests were 
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normalized by a log transformation for further analysis. The log trans-
formed results showed a normal distribution. The mean log titre was 
1.85 (i.e. 71 units) with a standard deviation of 0.24. This resulted 
in a coefficient of variation of 13%. This indicates that our labora-
tory standard and method of testing of RIF activity are reliable. Re-
search referencence preparation G-002-904-511 was used as a reference 
for the MIF assay in L929 cells, and preparation 69/19 as human inter-
feron reference in RSb cells. Hence the activities of these interfe-
rons were expressed in international reference units. 
Growth inhibition assay 
The growth inhibitory activity of interferon was measured with a dye 
elution assay. In summary, approximately 105 cells were seeded in 6 em 
petri dishes in 5 ml OMEM. supplemented with 10% FCS and the appropriate 
interferon dilution was added. When the untreated controls reached 
semiconfluency, the incubation was terminated and the cells were 
stained with crystal violet. Because the uptake of crystal violet by 
cells was directly related to the number of cells, growth inhibition 
was estimated by extracting the dye with 2-methoxy-ethanol and compa-
ring the E550 of the elutions from treated and control cultures. 
Results 
':, 
Factors influencing RIF production 
The influence of the challenge dose of NOV on the interferon production 
by REC is shown in Table 4. The interferon production increased with 
increasing challenge doses. The highest production was obtained with 
the highest challenge dose tested (102· 4 PFU/cell). Routinely, however, 
we used a challenge dose of 30 to 50 PFU/cell. Employing this challenge 
dose, NOV-containing allantoic fluid could be used without concentra-
tion. 
The interferon-producing capacity of different rat cells challenged 
with NOV is shown in Table 5. The secondary REC and Ratec cells were 
the best producers. WIRA and RR1022 cells produced only moderate 
amounts of interferon. The same table shows that type and concentration 
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Table 4. Influence of challenge dose of NDV on interferon produc-
tion by REG 
Challenge dose (PFU/cell) 
10° 
100.5 
101.0 
101.4 
101.9 
102.4 
Interferon production (units/ml) 
102.6 
102.9 
102.9 
103.2 
103.2 
103.5 
Table 5. Interferon production by rat cells challenged by NDVt at 
di ffer•ent ser•wn concentrations 
Type of ce 11 s 
REG 
Passage 7 
Passage 10 
Passage 13 
Ratec 
Passage 40 
Passage 46 
Passage 52 
WIRA 
RR1022 
Serum concentration 
10% FCS 
10% NCS 
1% NCS 
10% NCS 
1% NCS 
10% NCS 
10% NCS 
t Challenge dose: 30-50 PFU/cell 
Interferon production 
(units/ml) 
102.9 
104.4 
104.0 
102.0 
102.6 
Table 6. Induction of interferon by poly!ri).poly(rC) in BEG employing different schemes of induction 
Interferon production during 
24 h after induction 
Interferon production during 
48 h after induction 
Poly{rl).poly{rC) 
(100 ~g/ml) 
<50 
50 
Superinduction scheme A (Billiau et al. 1973) 
Poly{rl) .. poly{rC) Superinduction Superinduction 
{10 ~g/ml) scheme A scheme B 
DEAE dextran 
( 100 ~g/ml) 
150 <50 <50 
<50 <50 <50 
Priming for 24 h with 3,000 units/ml. Induction \'lith poly{rl).poly{rC) 50 ~g/ml for 1 h. After induc-
tion treatment \'lith cycloheximide 10 ~g/ml for 5 h, the last 2 h combined \'lith actinomycin D 1 ~g/ml. 
Superinduction scheme 8 (Wiranowska-Stevtart et al. 1977) 
Induction for 1 h with 100 ~g/ml poly{rl).poly{rC) plus 50 ~g/ml cycloheximide. Cycloheximide alone 
for 2 h. Thereafter, for 3 h cycloheximide combined with 50 ~M-5.6-dichloro-1-s-D-ribofuranosyl benzi-
midazole (ORB). Finally, for 18 h treatment with 40 ~M-DRB. 
N 
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of serum and omitting serum from the culture medium did not influence 
production. 
Poly(ri).poly(rC) is a potent inducer of interferon in vitro. In 
Table 6 the interferon production in rats cells challenged with poly(ri). 
poly(rC) is shown. Compared with NOV, poly(ri).poly(rC) alone proved a 
poor inducer of interferon in REC. The inducing capacity could only 
s 1 i ghtly be increased by adding di ethyl aminoethyl (DEAE) dextran or by 
priming. The superinduction schemes, successfully employed in human 
embryonic cells, actually inhibited interferon production in rat cells. 
Concentration and partial purification of RIF 
Ammonium sulphate has been widely used to precipitate interferons from 
different species. In Table 7 the effect of various ammonium sulphate 
concentrations on the precipitation of RIF is shown. Some activity 
TahZe 7. Preeipitation of RIF by r:urononiwn sulphate 
Saturation with Interferon in super- Interferon in preci-
ammonium sulphate(%) natant(units/100 ml) pitate (units/10 ml) 
0 102.3 
25 102.6 103.0 
40 101.8 103.8 
55 <10 103.9 
70 <10 104.0 
85 <10 104.4 
100 <10 104.4 
precipitated at 25% and the precipitation was complete at 85% satura-
tion. The precipitation of RIF at 85% saturation of ammonium sulphate 
appeared independent of pH in the range of pH 2.0 to pH 7.5 (results 
not shown). RIF activity could also be precipitated with zinc acetate 
at a concentration of 0.02 M. Zinc acetate precipitation of RIF resul-
ted in a higher specific activity (Table 8). The preparations used in 
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Table 8. Flow sheet for partial purification of RIF 
Initial: 100 ml crude rat interferon 
120 units/ml 
activity 102 units/mg protein 
Ammonium sulphate precipitation 
method 
Precipitate with (NH4)2S04 
added to 85% saturation 
Centrifuge 60 min at 10,000 
rev/min 
Dissolve precipitate in 10 ml 
PBS 
Dialyse extensively against 
PBS 
Centrifuge for 30 min at 10,000 
rev/min 
Steri 1 i ze by Mi 11 i pore fi 1 trati on 
Zinc acetate preci pi tati on method 
Precipitate with zinc acetate 
added to 0.02 M 
Centrifuge 60 min at 2,000 
rev/min 
Dissolve precipitate in 10 ml 
0 _ 2 N HCl 
Dialyse first against saline, 
then against PBS 
Centrifuge for 30 min at 10,000 
rev/min 
Steri 1 i ze by Mi 11 ipore filtration 
Final: 10 ml purified rat interferon 
68,000 units/ml 68,000 units/ml 
Activity 105.4 units/mg protein Activity 105-8 units/mg protein 
the present study were concentrated and purified by zinc acetate pre-
cipitation. No loss in activity was encountered .during this procedure. 
On the contrary, both methods of precipitation resulted in an unexpec-
ted increase in activity, as can be seen in Tables 7 and 8. 
Stability of RIF 
RIF appeared stable when stored at -70° C. Our laboratory standard 
stored this way in the presence of 10% FCS showed no loss in antiviral 
activity during a 2-year period. Fig. I shows the stability in the 
presence of 1% FCS at other temperatures. At 0° C no loss in activity 
was observed during 24 h incubation. At a room temperature of 20° C 
activity started to decrease after 4 h. One hour at 37° C resulted in 
a 50% loss in activity. Heating at 100° C destroyed all activity after 
15 min. Table 9 shows the effect of freezing and thawing on the anti-
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Fig. I. Influence of temperature on antiviral activity of RIF. RIF 
was incubated in DMEM supplemented with 1% FCS at the temperatures 
indicated: A= oo C; • = 200 C; • = 370 C; l:J. = 560 C; o = 1000 C. 
The maxirrrwn incubation time at 1000 C was 1 h, at the other tempe-
ratures 24 h. Samples were taken at the time-points indicated and 
irmnediateZy tested for interferon activity. Unincubated samples., 
which were kept -frozen until immediately before testing~ served as 
controls. 
Table 9. InfZuenc:e of freezing a:nd thawing on antiviral aetivity 
of RIF 
No. of times frozen and thawed Interferon activity (units/ml) 
l 102.2 
3 102.2 
5 101.9 
7 101.9 
The R!F preparation was diluted in DMEM supplemented with 1% FCS 
and frozen at -700 C. The sample was thawed in a waterbath at 370 C. 
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viral activity of interferon. Three cycles of freezing and thawing did 
not have any effect on activity. Seven cycles resulted in the loss of 
half of the activity. 
Characterization and species-specificity of RIF 
Table 10 shows that the antiviral activity in our preparations met the 
following criteria for an interferon. It was resistant to pH 2.0, sen-
sitive to trypsin treatment, and inactive in heterologous mouse and 
human cells. Rat cells could be protected against both VSV and vaccinia 
virus. 
Table 10. Characterization of RIF 
Activity 
Initial preparationt 
Treated with trypsin~ 
Activity against vaccinia 
Activity in L929 cells 
Activity in RSb cells 
Units/ml 
104.5 
<10 
104.0 
<10 
<10 
~Treated at pH 2.0 for 5 days to inactivate NOV 
Treated for 1 h at 370 C with 0.25% trypsin 
In Table 11 the antiviral activity of rat and human interferons in 
different rat cells is compared. The ability of these interferons to 
protect cells against the cytopathogenic effect of both VSV and herpes 
virus was tested. To protect Ratec cells against VSV, the least amount 
of RIF was necessary. The lowest protection against this virus was 
encountered in RUC II cells. ROS and RR1022 cells were equally well 
protected when the RIF activity was measured with herpes virus as chal-
lenge virus. Ratec cells were the least sensitive for the RIF protec-
tive effect against herpes virus. Apparently, there was no correlation 
between protection against VSV or herpes induced by RIF in these cells. 
Table 11. Antiviral activity of rat and hwnan interferons in rat oells of different origin 
Type of interferon and challenge Highest dilution giving 50% protection 
virus 
Ratec RUC II RSC ROS RN XC RR 1022 \HRA 
RIFt vsv 104.8 102.8 103.4 103.9 103.4 104.0 104.0 103.6 w 
103.8 ns~ 104.7 104. 7 104.1 N RIF Herpes ns ns ns 
HLI VSV and herpes <10 <10 <10 <10 <10 <10 <10 <10 
HFI VSV and herpes <10 <10 <10 <10 <10 <10 <10 <10 
t 104·8 units/ml ~ not sensitive (virus does not produce cytopathogenic effects in these cells) 
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Fig. II. Antiviral effect of RIF in seoondary REG pretreated with 
10" units of HLI. The aotivity of an RIF preparation in REG pre-
treated with HLI was measured as described in Material and Methods. 
The extinction of u:ntreated REG ( •-----•) is compared to that of 
REG treated with 103 units of HLI ( e • J. 
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Fig. III. Influenoe of rat and hwnan interferons on the growth of 
seoondary REG. The inhibition of the growth of REG by RIF (e), 
HLI ( •), and HFI ("' J was measured as described in Material and 
Methods. 
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HFI nor HLI had an antiviral effect in rat cells. In Fig. II the 
antiviral effect of RIF in REC pretreated with HLI is compared with 
the antiviral activity in untreated rat cells. There was no effect of 
HLI on the antiviral activity of RIF. Similar results were obtained 
when the cells were pretreated with HFI or when cells were incubated 
with RIF in the presence of either human interferon at a concentration 
of 103 units/ml. RIF also inhibited the growth of cells of the own 
species (Fig. III). 103 units of RIF/ml inhibited the growth of REG 
by 50%. Human interferons also lacked this activity in rat cells. 
Discussion 
This study shows that a high challenge dose of NOV is necessary to 
induce reasonable amounts of interferon in rat cells. When challenged 
with NOV, secondary REC and Ratec cells were the best producers of 
interferon of all cells studied. 
Serum in the culture medium is a major source of impurities in inter-
feron preparations produced in vitro. We demonstrated that the produc-
tion of RIF was not affected when serum was omitted from the tissue 
culture medium. This made it possible to produce RIF of a high activity 
with the use of a single purification and concentration step. 
Poly(ri).poly(rG) was a very poor inducer of RIF in REG. Addition of 
OEAE dextran only slightly enhanced the inducing capacity of poly(ri). 
poly(rC). Alone or combined with OEAE dextran it has also been reported 
to be a poor inducer of interferon when perfused through rat lungs 
(Tilles & Braun, 1973). It was not possible to enhance the interferon 
production by poly(rl).poly(rG) employing methods of superinduction 
successfully used in human cells (Billiau et al. 1973; Wiranowska-
Stewart et al. 1977). 
The properties of our RIF differed from those of the preparation of 
Schanne (1966), who found that the interferon activity was precipitated 
by ammonium sulphate at 100% saturation only, and that the interferon 
activity could not always be recovered when precipitated by 0.02 M-
zinc acetate. He also reported a 50% loss of interferon activity after 
treatment with 0.15 M-perchloric acid and complete loss of activity 
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after 2 cycles of freezing and thawing. In the present study, RIF com-
pletely precipitated at 85% saturation of ammonium sulphate. Interferon 
activity could easily be recovered from the 0.02 M-zinc acetate preci-
pitate. 0.15 M-perchloric acid could be used to inactivate NOV without 
any loss in interferon activity and the antiviral activity of inter-
feron was not affected by 3 cycles of freezing and thawing. 
There was a considerable increase in the total amount of RIF activity 
when our preparations were concentrated. This could not be explained by 
interferon induction by residual NOV in our preparations. Inoculation 
in embryonated eggs failed to eliminate live NOV and the preparation 
lacked activity in L929 cells, which are sensitive to interferon induc-
tion by both live and inactivated NOV. An antagonist of interferon 
activity produced in embryonic and other tissues has been described 
(Fournier et aZ. 1972). It is possible that during concentration this 
antagonist of interferon was lost. Another explanation of this increase 
in activity upon concentration can be that interferon molecules asso-
ciate or combine with other substances, resulting in increased anti-
viral activity. 
The influence of temperature on the antiviral activity of rat inter-
feron reported here is in good agreement with other studies (Schonne, 
1966; Billiau & Buckler, 1970). Activity of RIF in cells of other 
species, especially mouse cells, has been reported by several groups 
(Biernacka & Lobodziiiska, 1973; Lobodziiiska et aZ. 1973; Illinger et 
al. 1976). In the present study this cross protection could not bees-
tablished. This difference may be explained by the comparatively high 
purity of our interferon preparation. There was also no activity of 
human interferon in rat cells, as reported by others ( Ouc-Goi ran et aZ. 
1971; Chany, 1976). Neither the antiviral activity of HFI nor the inhi-
bition by Hll or RIF in rat cells was encountered. Probably, the purity 
of the interferon used plays a role. The purity of the human inter-
ferons employed in these studies was not always explicitly stated, but 
can be assumed to be comparatively low. R!F showed the same anticellu-
lar activities as reported for interferons of other species (Paucker 
et aZ. 1962). 103 units/ml of RIF inhibited the growth of rat cells 
by 50 %. From these results we conclude that the rat interferon system 
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does not differ from that of other species as has been concluded from 
earlier reports. 
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CHAPTER 3 
INFLUENCE OF INPUT MULTIPLICITY OF INFECTION ON THE ANTIVIRAL 
ACTIVITY OF INTERFERON 
The purpose of this study was to investigate the protective effect of 
interferon on the survival of virus-infected cells. 
This study was achieved by cooperation of the Department of Virology, 
Erasmus University Rotterdam and the Virology Section of the Primate 
Centre TNO, Rijswijk. 
This chapter is based on: 
'Influence of multiplicity of infection on the antiviral activity of 
interferon' by L.Stitz & H.Schellekens, published in Journal of General 
Virology 46, 1980, 205-210. 
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lntroducti on 
Early reports on the influence of the multiplicity of infection (MOl) 
on the antiviral state induced in vitro by interferon are conflicting. 
Protection of cells against vaccinia virus (Lindenmann & Gifford, 19631 
Sendai virus (Finter, 1964), polio virus (Hallum & Youngner, 1966), 
Semliki forest virus (Finter, 1969) and fowl plague virus (Isaacs, 
1959) as the result of interferon treatment was reported to be i nde-
pendent of the MOl. Sellers and Fitzpatrick (1962) established that 
the amount of interferon needed to protect rhesus monkey kidney cells 
against the cytopathogenic effect of bovine enteritis virus was 
directly related to the MOl. The same results were reported by Ho 
(1962) for VSV. Hallum and Youngner (1966) and Ke et al. (1970) failed 
to demonstrate this dependence for VSV. 
The early results are, however, difficult to compare because it is 
not always clear what the exact MOl was and whether the antiviral acti-
vity was mediated by interferon. The methods used to measure the anti-
viral activity of interferon also differed widely. 
More recent work by Oie et al. (1975) for murine cytomegalovirus, 
Postic and Dowling (1977) and Holmes et al. (1978) for varicella-zoster 
virus showed convincingly that inhibition of virus production or cyto-
pathogenic effect by interferon was reduced when the MOl increased. 
Yamamoto et al. (1975) reported that the relative number of interferon-
treated cells positive forT-antigen was greater-when the MOl of SV40 
was higher. These recent reports, however, relate only to DNA viruses. 
All previous studies were confined to one type of virus and interferon 
of one species. 
This study was undertaken to determine the influence of the MOl on 
the protection of cells provided by interferon against both DNA and 
RNA virus infections. 
Material and Methods 
Cells 
L929 cells, Vera cells and human embryonic lung (HEL) cells were pur-
chased from Flow Laboratories (Irvine, Scotland) and had undergone an 
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unknown number of passages in our laboratory. Strains of rhesus monkey 
skin fibroblasts, obtained from biopsies taken from the chest and pro-
cessed as described by Perrin et al. (1977), were designated as RSF 
3314, 3504, 3544 and 3546 and were in their 30th to 40th passage. The 
continuous line of rat cells, derived from subcultivation of whole rat 
embryo cells, and designated as Ratec cells, is described in chapter 2; 
it was used in the experiments at about the 70th passage. All cell lines 
were grown as monolayers in 75 cm2 Falcon plastic flasks at 37° C in a 
moist atmosphere containing 5% co2. The growth medium consisted of 
OMEM supplemented with 10% FCS heated at 56° C for 30 min, bicarbonate, 
1% glutamine and antibiotics (penicillin, 75 units/ml- 1, streptomycin, 
75 mg/ml- 1). 
Interferons 
An HLI preparation, kindly provided by Or.K.Cantell (Central Public 
Health Laboratory, Helsinki, Finland) and prepared as previously des-
cribed (Cantell & Hirvonen, 1978), had an activity of 105· 9 units/mg 
protein. All activity was expressed in international reference units 
in terms of the reference preparation 69/19. 
MIF was prepared as described by Allen et aZ. (1976) and had an acti-
vity of 106·0 unitsjmg protein. All activity was expressed in interna-
tional reference units in terms of the reference standard G-002-904-
511. 
RIF was prepared in Ratec cells challenged with NOV and was partially 
purified. The preparation had an activity of 105· 7 units/mg protein 
when tested against an internal laboratory standard. Details of the 
production, purification and standardization of this interferon are 
described in chapter 2. 
Viruses 
The herpes virus strain used was isolated in our laboratory from a 
patient with a cold sore and was identified as herpes hominis type 
by the immunofluorescence technique. The virus was propagated in L929 
cells and the 3rd passage was used in this study. Two strains of vac-
cinia virus were used, the Dutch vaccination strain (Hekkeret aZ .1973) 
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(Rijksinstituut voor de Volksgezondheid (RIV), Bilthoven, The Nether-
lands) and the WR strain. The WR strain was also passaged in L929 cells. 
ECHO virus type 6 was obtained from the NIH, Bethesda Md., USA (Cat. 
no. V-039-001-20). This virus was routinely grown in Vera cells. VSV, 
Indiana strain, was propagated in L929 cells at a low MOl. Clones of 
VSV, designated 1 to 7, were prepared by the dilution technique. All 
virus titres given in the text were determined in cells of the same 
type as those used in that particular experiment, employing a micro-
titration technique. 
Assessment of interferon activity 
Except otherwise stated in the legends of the tables, the method used 
to determine the antiviral activity of interferon was as follows. The 
cells were grown in microtitre plates in DMEM + 10% FCS at a concentra-
tion of approximately 4 x 104 cells per well. l>hen monolayers formed, 
the supernatant was removed and interferon added in twofold dilutions 
in m.1£M + 1% FCS using 8 wells for every interferon dilution. After 
overnight incubation, the supernatant was removed and the cells were 
infected with different MOl, using 10 wells for each concentration. 
The supernatant was removed after 48 h of incubation and the cells 
were stained with crystal violet. The interferon dilution protecting 
50% of the cells at the different MDI used was assessed visually. When 
no protection was established, the amount of interferon necessary to 
protect 50% of the cells was assumed to be greater than the highest 
concentration used. When all cells infected with a certain MDI were 
protected, the amount of interferon needed was assumed to be less than 
the lowest concentration used. 
Results 
Influence of MOI on the pr>otection of cells by interferon 
To study whether the ~101 has an effect on the protection of cells by 
interferon, experiments with different viruses and 8 different types 
of cells were carried out (Table 12). At an MOl of 100 TCID50;cell, no 
protection was seen in any of the systems with the interferon concen-
Table 12. Units of interferon protecting 50% of cells of different species against the CPE of 
different MOI of VSV 
Challenge Cell type 
dose (MOl) Mouse Rat Human Monkey 
l929 Ratec HEL Vero RSF 3314 RSF 3544 RSF 3546 RSF 3504 
100 > 200 > 200 > 2000 > 2000 > 2000 > 2000 > 2000 > 2000 
10 > 200 3 250 > 2000 > 2000 > 2000 > 2000 125 
I > 200 I 30 2000 250 34 67 67 
0.1 50 0.8 < 4 500 68 8 17 34 
Cells were gr01;n in microtitre plates and treated with interferon from the same species (except mon-
key cells which were treated with Hll);after overnight incubation, the cells 1;ere infected with VSV 
at the 1401 indicated 
.,. 
~ 
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trations used. When cells were infected with an MOl of 1, most cell 
types could be protected by interferon. At MOl < 1 much less units of 
interferon were needed to protect 50% of the cells. 
In Tab 1 e 13 the effect of the r~OI of VSV, herpes, ECHO and vaccinia 
virus on the amount of interferon necessary to protect cells of diffe-
rent species is shown. The protection was challenge dose-dependent in 
Table 15. Unite of interferon protecting 50% of ceZZs of different 
speeies against the CPE of VSV~ herpes~ ECHO and vaccinia virus 
Challenge Cell type 
dose (MOl) L929 Ratec Vero RSF 3314 
VSV 
100 > 200 > 200 > 2000 > 2000 
10 > 200 3 > 2000 > 2000 
1 50 1 2000 250 
0.1 25 0.8 500 67 
Herpes 
0.01 3 > 2000 > 2000 n.d. * 
0.001 1 500 60 n.d. 
0.0001 0.25 16 8 n. d. 
0.00001 n.d. 4 < 4 n. d. 
ECHO 6 
10 t 250 > 2000 
1 60 > 2000 
0.1 8 1000 
0.01 < 4 67 
Vaccinia 
1 > 500 > 200 > 2000 > 2000 
0.1 > 500 200 > 2000 > 2000 
0.01 > 500 6 > 2000 > 2000 
0.001 > 500 0.5 > 2000 > 2000 
"' t n.d. = not done 
- = no CPE with this virus 
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all cells of the species studied, irrespective of the type of virus. 
Protection against ECHO virus and VSV by interferon was established 
when the MOl was~ 1 TCID5o/cell. The cytopathogenic effect (CPE) of 
vaccinia virus was not inhibited in human, monkey or mouse ce·ns trea-
ted with an appropriate interferon, but was inhibited in interferon-
treated rat cells at an r.101 of< 1. The lack of protection of monkey 
and mouse cells against vaccinia virus was not because these cells are 
insensitive to interferon, as they were protected by interferon against 
VSV, herpes, and ECHO virus. Both vaccinia strains studied showed the 
same pattern of sensitivity. 
The MOl-dependent protection by interferon might be explained if the 
virus populations studied were mixtures of interferon-sensitive and 
interferon-resistant viruses. However, when 7 different clones of VSV 
were compared, their sensitivity to interferon was similar (Table 14). 
Tab~e 14. Units of interferon protecting 50% of L929 cells against 
the CPE of different clones of VSV 
Challenge Clones of VSV 
dose (MOl) 1 2 3 4 5 6 7 
100 n. d. n. d. > 500 n.d. n.d. > 500 n.d. 
10 > 500 > 500 > 500 > 500 > 500 125 > 500 
1 > 500 > 500 64 500 250 16 > 500 
0.1 16 32 16 32 32 16 32 
0.01 8 16 < 4 < 4 16 8 16 
0.001 < 4 < 4 < 4 < 4 < 4 < 4 8 
0.0001 < 4 < 4 < 4 < 4 < 4 < 4 8 
0.00001 < 4 < 4 < 4 < 4 < 4 < 4 4 
None were protected at an ~101 of> 1, but all were protected when the 
MOl was 2 1. Another possibility is that interferon permits the selec-
tive growth of interferon-insensitive virus subtypes. Therefore, VSV 
was passaged at high MOl in interferon-treated cells and the inter-
feron-sensitivity of this virus was compared with the parental strain. 
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TabZe 15. Units of interferon protecting 50% of L929 eeZZs against 
VSV grown in interferon-treated cells 
Challenge VSV passaged in VSV passaged in i nte~-
dose (MOl) untreated L929 cells feror.-treated cells 
10 128 512 
l 64 32 
0.1 16 8 
0.01 8 4 
0.001 4 < 2 
*Before challenge with VSV at the 1·10! indicated, virus was passaged 
3 times at an 110! of 102 TCID5o/cell in L929 cells with 500 units 
of interferon 
Table 15 shows that the interferon-sensiti:vity was not influenced by 
this treatment. 
Influence of time of incubation on the antiviral effect of interferon 
The duration of the antiviral effect of interferon at different MOl in 
L929 cells is shown in Table 16. Again, there was no protection against 
the high MOl of VSV at the interferon concentrations studied. Protec-
tion could be induced at an t40! .:_ 1 TCID5o/cell, but this protection 
was only temporary. At an MOl of 0.1 TCID5o/cell ,protection for 4 days 
required 20 times more interferon than protection for 2 days. It was 
not possible to protect cells at this MOl for more than 4 days with 
the interferon concentrations studied. 
The need for more interferon for 1 anger protection caul d be due to 
the fact that the antiviral state of cells decreases with time after 
the removal of interferon-containing medium. However, as shown in Table 
17, there was no difference in the antiviral effect of interferon when 
cells treated only before viral challenge were compared with cells 
treated with interferon before, immediately after and again one day 
after infection. It has also been suggested that the enhanced anti-
viral effect of interferon at low 140! is caused by extra interferon 
induced by the infecting virus (Ho, 1962). 
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Table 16. Units of interferon protecting 50% of L929 ceZle at 
different times after infection with VSV 
Cha 11 enge Hours after infection 
dose (MOl) 24 48 72 96 120 144 
1000 > 512 > 512 > 512 > 512 > 512 > 512 
100 8 > 512 > 512 > 512 > 512 > 512 
10 n.d. > 512 > 512 > 512 > 512 > 512 
1 n. d. 32 512 > 512 > 512 > 512 
0.1 n. d. 16 32 512 > 512 > 512 
0.01 n .d. 8 16 64 128 128 
0.001 n.d. 1 1 16 16 < 1 
0.0001 n.d. 1 1 1 1 < 1 
Table 1?. Effect of the presence of interferon during the replica-
tion of VSV on the units of interferon protecting 50% of L929 cells 
Cha 11 enge No interferon present Interferon present * 
dose (1~01) during viral growth during viral growth 
1000 > 200 > 200 
100 > 200 > 200 
10 200 100 
1 50 50 
0.1 25 25 
0.01 13 13 
* Interferon was addition a 11y added to the cells after infection 
To test this hypothesis, L929 cells were treated with interferon and 
24 h later prechallenged with VSV at the low MOl of 0.001 TC!Dso/cell. 
Precha11 enged and control non-precha 11enged ce 11 s wet·e infected with 
different MOl of VSV 24 h after prechallenge. Table 18 shows the com-
parison of the antiviral state induced by interferon in prechallenged 
and non-prechallenged cells. There was no difference in the amount 
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of interferon needed to protect these cells against different MOl of 
vsv. 
Tahle 18. Effect of prechallenge mth VSV on the units of inter-
feron protecting 50% of VSV-infected L929 cells 
Challenge dose Non-prechallenged cells Prechallenged cells* 
(1101) (units interferon) (units interferon) 
100 > 500 > 500 
10 > 500 > 500 
1 30 30 
0.1 1 1 
* Before infection with the MOl indicated, the cells were prechal-
lenged with VSV at an ~101 of 0.001 TCID5Q/cell 
Discussion 
This study shows that the amount of interferon needed to protect cells 
of different species against the cytopathogenic effect of both DNA and 
RNA viruses is directly related to the amount of virus the cells are 
challenged with. This MOl-dependent protection by interferon could not 
be explained in terms of differences in interferon sensitivity of 
clones within the population of viruses studied or in terms of selec-
tion of interferon-resistant types of viruses (see Tables 14 and 15). 
Viruses grown in cells treated with interferon had the same interferon 
sensitivity as the parental virus. 
It has been suggested (Ho, 1962) that interferon is more active at a 
low MOl because 'extra' interferon is then induced by the infecting 
virus. Using double challenge experiments., we were unable to establish 
such 1 extra 1 protection. 
A decrease in the antiviral state of the cells with time cannot be 
responsible for the failure of interferon to protect against the cyto-
pathogenic effect of the viruses. Additional interferon administration 
during the incubation period did not influence the results. At the 
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concentrations studied, interferon protected against viral cytopatho-
genicity only when cells were challenged with an MOl~ 1 TCIDso/cell. 
This protection lasted for a certain time only, dependent on the r10I, 
and this indicates that, even when cells are infected with a single 
virus particle only, interferon is not capable of preventing cell 
death. The only effect of interferon seems to be a reduction of virus 
production. This only postpones the moment at which all cells will be 
infected. 
The decrease in the production of prooeny virus by interferon is 
caused by inhibition of viral replication at the transcriptional or 
translational level, depending on the virus-cell system used (Friedman, 
1977). Apparently, inhibition of viral replication by interferon does 
not lead to protection of those cells. Various explanations can be 
considered: (1) The production of mature virus particles may be sup-
pressed by interferon, while the functions interfering with the cellu-
lar metabolism that lead to cell death are unaffected (r1arcus & 
Sekellick, 1976); (2) There is an overall reduction in viral replica-
tion by interferon which leads to diminished production of virus, but 
remaining viral production of virus is sufficient to interfere with 
cellular metabolism to such an extent that the cells cannot survive; 
(3) The infecting virus directly inhibits the antiviral activity of 
interferon (Lindenmann, 1959). Experiments are in progress to test 
these hypotheses. 
Finally, this in vitro influence of the f10! on the antiviral activity 
of interferon is likely to play a role in vivo too. Interferon in vivo 
is more effective in preventing than in curing viral infections and has 
little effect when administered late (Finter, 1973). During well-esta-
blished viral infections in vivo, the virus challenge to cells is 
probably so high that interferon cannot prevent cell death. One should, 
however, be cautious in extrapolating in vitro effects of interferon to 
in vivo effects. Rhesus monkeys can be protected against vaccinia virus 
infection by interferon, while the same interferon preparation is not 
effective in inhibiting the same virus in vitro (This thesis, chapter?~ 
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CHAPTER 4 
CELL GROWTH INHIBITION BY INTERFERONS 
The purpose of this study was to investigate the inhibitive activity 
of interferon on cell division of haemopoietic tissue and to observe 
this anticellular effect during conditions of viral inflammation. 
This study was achieved by cooperation of the Departments of Pathology, 
Virology, Haematology and Internal Medicine, Erasmus University Rotter-
dam. 
This chapter is based on: 
'The influence of interferon preparations on the proliferative capa-
city of human and mouse bone marrow cells in vitro by E. van 't Hull, 
H.Schellekens, B.Lowenberg & M.J.de Vries, published in Cancer 
Research 38, 1978, 911-914; 
'Cytotoxicity of interferon and viral inflammation' by H.Schellekens 
& W.Weimar, published in International Virology IV, 1978, 110. 
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General Introduction 
The first 'non-antiviral' activity of interferon to be reported was 
the inhibition of cell multipTication (Paucker et al. 1962). It has 
been heavily disputed in the past whether interferon itself or impuri-
ties were responsible for this anticellular effect. Now that pure 
interferons are available, it has become clear that the anticellular 
factor shares all biological and physico-chemical properties with the 
antiviral factor and, apparently, is interferon (Knight, 1976). 
This chapter contains two studies on the inhibition of cell multi-
plication by interferon. An obvious application of interferon in man 
is the prevention of viral infections in the immunocompromised host. 
However, in these patients the bone marrow potential may be restricted 
and further suppression of the bone marrow by interferon is undesirable. 
The first part of this chapter deals with the in vitro toxicity for 
bone marrow cells of interferon prepared for clinical use. In the 
second part aspects of the biological significance of the anticellular 
effect are studied. 
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INFLUENCE OF INTERFERON PREPARATIONS ON THE PROLIFERATIVE CAPACITY OF 
HUMAN AND MOUSE BONE MARROW CELLS IN VITRO 
Introduction 
Viral infections present a major problem in primates (humans and rhesus 
monkeys) with primary immune deficiencies and those subjected to immu-
nosuppressive therapy. It has become evident that the severity and in-
cidence of viral infections are particularly prominent in patients who 
have been treated with immunosuppressive regimens following allogeneic 
bone marrow transplants (Balner et aZ. 1968; van Bekkum et aZ. 1978). 
The further development of bone marrow transplantation in humans is 
largely dependent on the possibility for control or prevention of these 
complications (Thomas et aZ. 1977). Recently, the successful applica-
tion of interferon as an antiviral drug in humans has been reported 
(Desmyter et aZ. 1976; Greenberg et aZ. 1976; Jones et aZ. 1976). 
Interferon preparations in high concentrations, however, inhibit 
cell division. Therefore, one must be aware of possible bone marrow 
toxicity (Cheeseman et aZ. 1976) because the bone marrow reserve may 
be severely limited, particularly in patients treated with bone marrow 
transplantation and cytotoxic agents. Testing of the clinically 
applied interferon preparations for bone marrow toxicity prior to 
clinical use will be important. This can hardly be achieved in vivo in 
man. Therefore, one must rely on in vitro assays. Colony-forming cul-
tures, in which progenitor cells are induced to proliferate and diffe-
rentiate may meet the criteria of a convenient assay. 
HLI and HFI and their effects on haemopoietic myeloid and erythroid 
progenitors in culture were studied. The inhibition of the formation 
of granulocytic-macrophage colonies and erythroid colonies during ex-
posure of marrow cells to interferon was investigated. The effect of 
mouse L-cell interferon on the formation of erythroid as well as gra-
nulocytic colonies in mouse bone marrow was also included in the study 
in order to compare the species specificity of the interferon prepara-
tions. 
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Material and Methods 
Interferon preparations 
HLI was kindly supplied by Or.K.Cantell (Central Public Health Labora-
tory, Helsinki, Finland). The interferon was induced and semi purified 
as described before (Cantell, 1970). The batch used had an activity of 
6 x 106 units/ml and a protein concentration of 7 mg/ml. HFI was kindly 
supplied by Or.V.G.Edy (Rega Institute, University of Leuven, Leuven, 
Belgium), was induced and semipurified as described before (Billiau et 
al. 1973) and had an activity of 106 units/20 mg of protein. A control 
preparation was prepared from human plasma protein fraction V, follo-
wing the same procedures as used for the manufacture of the interferon 
preparations. This preparation was also used as a control in in vivo 
studies in patients. Mouse interferon was induced with NOV in mouse 
L929 cells and prepared as described before (Allen et al. 1976). It 
had an activity of 106 units/mg of protein. Control preparations were 
prepared from L929 cell culture supernatant following the same proce-
dures as those used to prepare the interferon preparations. The inter-
feron preparations were diluted to the desired concentration in DMEM 
and were added to the cell suspensions as a part of the culture medium 
wherein the cells were cultured. 
Preparation of c:e ZZs 
Human bone marrow was obtained aseptically from patients requiring a 
diagnostic puncture. Patients were suffering from a variety of diseases, 
predominantly rna l i gnant tumours and infections; some patients manifested 
a mild anaemia. Blood was collected by venipuncture. The erythrocytes 
were removed from the nucleated bone marrow and blood cells by sedimen-
tation at unit gravity in 0.1% methyl cellulose (Methocel McDow Chemi-
cal Co., Midland,Michigan, U.S.A.) in DMEM (Flow Laboratories, Irvine, 
Scotland). 
Mouse bone marrow was obtained by dissecting the femurs of 6- to 8-
week-old female BALB/c mice. Bne of the ends was cut with scissors, and 
the marrow was flushed from the shafts. All cells were carefully washed 
with Hank's balanced salt solution after collection. 
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Mye~oid co~ony cu~tures for human ce~~s 
To determine the number of colony-forming units (CFUc) we adopted the 
culture method of Pike and Robinson (1970). The underlayers were pre-
pared by mixing 106 leucocytes with 1 ml of culture medium (0.5% agar, 
20% serum, and DMEM). The serum component contained equal parts of 
horse serum, FCS, and 3% Trypticase Soy Broth (Difco Laboratories, 
Detroit, Mich., U.S.A.). Thereafter, an overlayer containing themarrow 
cells in 0.25% agar in DMEM, supplemented with 20% serum, was pipeted 
on top of the leucocyte underlayers. After incubation for 14 days in a 
humidified atmosphere of 5% C02 - 95% air, the colonies were counted 
with an inverted microscope. 
Three petri dishes were used for each experimental point. 
Erythroid colony cultures from human cells 
Colony formation in plasma clots was determined according to themethod 
of ~1cLeod et aZ. (1974). Nucleated bone marrow cells in a concentration 
of 2 x 103;ml were suspended in medium containing DMEM, 20% FCS, 1% 
bovine albumin (fraction V; Sigma Chemical Co., St.Louis, ~1o., U.S.A.), 
2% asparagine, 0. 25 unit erythroprotei n (step II I; Connaught r~edi cal 
Laboratories, Willowdale, Ontario, Canada), and 10% bovine citrated 
plasma (Grand Island Biological Co., Grand Island, N.Y., U.S.A.). The 
cells were cultured in microtitre plates (C.A.Greiner und Sohne, Nur-
tingen, B.R.D.), and 0.1 ml of the cell suspension was incubated per 
well. 
The cultures were placed in an incubator under the same conditions as 
those used for the myeloid colony method. After 2.5 days of incubation, 
the clots were removed from the microtitre plates and stained with 
benzidine after fixation with 5% glutaraldehyde in phosphate-buffered 
saline (0.01 M isotonic NA2HP04-KH 2Po4 buffer, pH 7.0 to 7.2). 
Cell aggregates containing more than 8 cells were counted with the 
light microscope. The aggregates consisted of differentiated erythro-
blasts. Each experimental point represents the average colony counts of 
at least 10 whole clots. 
54 
Granulocytic-macrophage colony cultures of mouse cells 
The system was originally described by Bradley and Metcalf (1966). Nu-
cleated bone marrow cells were suspended in an agar solution (0.3%) in 
DMEM supplemented with 20% serum (consisting of equal parts of horse 
serum, FCS, and 3% Trypticase Soy Broth solution). 
One ml of this mixture containing 105 cells was plated per plastic 
petri dish (diameter 3.5 em). As a stimulator 0.1 ml of mouse fibro-
blast-conditioned medium was added to each plate. The dishes were 
incubated for 6 days under the same conditions as those for the other 
cultures. Thereafter, colonies were counted. 
Results 
HLI and HFI inhibited the formation of human erythroid colonies (CFUel· 
The extent of inhibition was linearly related to the dosage of inter-
feron (Fig. IV). 
0 
Units of intorferon/ml 
Fig. IV. Cytotoxic-ity of HFI ( 0) a:nd HLI (e) for human CFUe. 
Nine exf?er>iments; bars: SD. 
HLI and HFI preparations also suppressed the formation of CFUc 
(Fig. V). Inhibition of CFUe and CFUc by HFI was similar. Colony growth 
from both cell populations was reduced for 50% by 104 units/ml. 
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Units of intarfcron/ml 
Fig. V. Cytotoxic-ity of HFI ( o) and HLI (e) for hwnan CFU . Nine 
" experiments; bars: SD. 
However, HLI differed clearly from HFI: (a) it was significantly more 
toxic to human CFUc than to CFUe; (b) this interferon showed no or 
only minor inhibitive effect on murine CFUc and CFUe (Table 19). 
Table 19. Speeific~ty of the toxiG~ty of interferon preparations 
CFUc and CFUe of mouse bone marrow cellst 
Control 
1 X 104 U 
1 X 103 U 
1 X 102 U 
1 X 10 U 
Mock i nterf. 
HFI HLI 
CFU,f1cficells CFUc!105cells CFUe/l05cells CFUc/1cYcells 
202.3+24.7~ 100.0+10.0 202.3+24.7 100.0+10.0 
194.7+23.7 94.4+ 7.4 131. 3+20 .1 58.8+ 9.6 
203.4+26.6 98.6+11.4 177 .1+25.9 91.5+ 9.1 
209.9+24.4 101.5+ 7.4 191.2+21.9 102.9+10.4 
198.7+26.6 99.6+11.3 208.3+35.5 102.7+10.3 
197 .1+20 .1 102.4+ 8.2 
t Human bone marrow cells were not inhibited by mouse L-cell inter-
feron ~ Mean + SD 
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A third interferon preparation, produced in mouse L929 cells, was 
also investigated for its effect on human and mouse progenitor cells. 
Whereas mouse interferon showed inhibition of the colony growth of 
mouse CFUe and CFUc in a linear dose-effect relationship (Figs. VI and 
VII), it was not toxic for bone marrow (results not shown). 
This indicates that the toxicity of human interferon may be species-
dependent. 
0 
Uni~ of lntcrferon/ml 
Fig. VI. Cytotoxicity of mouse L-cell interferon for mouse CFU8 . 
Five experiments; bars: SD. 
Units of int<Jrfercm/ml 
Fig. VII. Cytotoxicity of mouse L-ceZZ interferon for mouse CFUc. 
Five experiments; bars: SD. 
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Discussion 
Interferon preparations inhibit CFUe and CFUc in vitro. HFI inhibits 
the formation of CFUc and CFUe in vitro at concentrations much larger 
than those needed for the establishment of the antiviral state of cells 
in vitro. The toxic concentration of HFI also exceeds the serum titre 
of interferon in patients treated with high doses of HFI (20 x 106 
units/ml fibroblast interferon daily, a serum titre rise of 30 units/ 
ml (V.G.Edy, personal communication)). The effect of HLI on CFUe is 
similar to that of HFI, but HLI is comparatively more toxic to CFUc. 
Only 10 units of HLI suffice to inhibit the growth of CFUc by approxi-
mately 40%, whereas as much as 104 units of HFI are needed to produce 
a similar reduction. Using a similar assay system, other investigators 
have reported that HLI preparations may be extremely toxic for CFUc 
in human bone marrow cultures (Greenberg & Mosny, 1977; Nissen et aZ. 
1977). To our knowledge, the effect of erythroid progenitors has never 
been investigated. 
Others have demonstrated in a different experimental system that the 
cytotoxic and antiviral activities of interferon preparations share 
many physico-chemical and biological characteristics (McNeill et aZ. 
1975; Knight, 1976). This may suggest that interferon itself is res-
ponsible for the cytotoxic effects. However, in view of the nonavail-
ability of completely purified interferon, one cannot be certain 
whether the cytotoxicity is due to impurities in the preparation. Com-
parison of the cytotoxic effect of HLI on mouse and human CFUc, respec-
tively, shows that this interferon is less toxic for mouse bone marrow, 
indicating a (cell- and species-)specific effect and not toxicity due 
to impurities. Therefore, the cytotoxic effect could be closely related 
to the antiviral effect of interferon (compare Fig. V and Table 19). 
The toxicity of HLI could pose a problem in clinical application 
because it is already apparent at lower than pharmacological concen-
trations. 
The finding that HLI is more toxic for CFUc than for CFUe is of inte-
rest in view of previous work of Einhorn and Strander (1977). They 
suggest that the inhibiting effects of interferon are specific for 
those target cells that are prevalent in the tissue in which the inter-
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feron is induced. 
The effect of mouse interferon on murine CFUe and CFUc is essentially 
similar to that of HFI on human bone marrow. The adverse effect of 
L-cell interferon on the colony formation has been reported to be less 
prominent than the effect of interferons from other murine sources. 
McNeill and Gresser (1973) explained this effect by a contamination of 
L-cell interferon with colony-stimulating activity, but in our material 
no significant colony-stimulating activity was present. 
No doubt, it will be necessary in the future to test the interferon 
toxicity on bone marrow for in vivo relevance. This should be done in 
direct comparison with clinical and haematological parameters, and this 
should finally establish the value of the method. Until the toxicity 
ratio of interferon has been more thoroughly established in in vivo 
studies, one must rely largely on extrapolation from in vitro tests. 
The above data imply that, in terms of marrow toxicity, HFI might 
represent a preferable choice over HLI, especially in patients with 
marrow insufficiency. 
59 
CELL GROWTH INHIBITION BY INTERFERON DURING CONDITIONS OF VIRAL INFLAM-
MATION, ESTABLISHED WITH A SIMPLE METHOD 
Introduction 
Apart from antiviral activity, interferon preparations show other ac-
tivities as well, such as alteration of the immune response in vitro 
and in vivo (Gresser, 1977; Finlay et al. 1977; Sonnenfeld et aZ.1977), 
activation of macrophages (Schultz et al.1977; Stebbing et al.1978) and 
inhibition of cell growth (Paucker et al.1962; Gresser et al. 1970; 
Gresser, 1977; this chapter). Because in these studies interferon pre-
parations certainly were not pure, it is uncertain whether interferon 
is responsible for these activities. However, it is now well establish-
ed that one glycoprotein causes both the antiviral activity and the 
inhibition of cell growth (Knight, 1976; Stewart et al. 1976; Buffett 
et al. 1978). 
In vitro interferon inhibits cell growth in comparatively high con-
centrations only (Paucker et al. 1962; Gresser et al. 1970; this chap-
ter). In vivo these concentrations are attained at this site of the 
viral infection only (Finter, 1973). One aim of this study was to 
mimick some of the local conditions of a viral infection in vitro and 
study their effect on growth inhibition. The commonly used techniques 
to quantitate inhibition of cell growth are cell counting and measuring 
3H-TdR incorporation. Especially when growth inhibition in monolayers 
is tested, these methods are time-consuming. We have studied growth 
inhibition quantitatively by measuring the dye uptake by monolayers 
in vitro. 
Material and Methods 
Cells 
RSb cells were a kind gift from Dr.T.Kuwata (Chiba University, Chiba, 
Japan). The origin and characteristics of these transformed human 
cells have been described elsewhere (Kuwata et al. 1976). 
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Interferon and interferon titration 
HLI was provided by Dr.K.Cantell (Central Public Health Laboratory, 
Helsinki, Finland). This partially purified interferon had an activity 
of 105 ·9 units/mg protein. HFI was kindly supplied by Dr.A.Billiau 
(Rega Institute, University of Leuven, Leuven, Belgium) and had an 
activity of 106 units/mg protein. Interferon was titrated as described 
before, using RSb cells (Schellekens et aZ. 1975). Interferon activity 
was expressed in international reference units (U/ml). 
Quantitation of cell growth inhibition 
The cell growth inhibition was measured by a modification of a method 
described by Armstrong (1971) to quantitate the antiviral activity of 
interferon by dye uptake and elution. 
RSb cells were seeded in 6 em petri dishes and interferon was added 
in appropriate concentrations. Cells were incubated until the control 
cultures had reached semiconfluency (in general after 3 to 4 days). 
After incubation, the dishes were drained and the cells were washed 3 
times with phosphate buffered saline. The cells were stained for 20 min 
with a dye solution (5 g crystal violet (Merck), 8 g NaCl, 50 ml for-
maldehyde solution (Merck), 500 ml ethanol, water to 1000 ml). After 
staining, the dishes were washed extensively with tap water and 
allowed to dry. 5 ml 2-methoxy-ethanol were added to extract the crys-
tal violet. Up to 24 h were needed to extract all dye. When the elution 
was completed, the absorbance of the extracted dye was measured at 
550 nm. Petri dishes without cells showed minimal absorption of crystal 
violet, so all crystal violet eluted was considered as eluted from 
cells. The anticellular activity of interferon preparations was also 
assayed by measuring the 3H-TdR uptake, according to Fuse and Kuwata 
(1976). 
Virus 
VSV, Indiana strain, was routinely grown in our laboratory in monolayer 
cultures of L929 cells. VSV was stored frozen at -70° C. Titres were 
expressed as TC!Dso, established in RSb cells using standard techniques. 
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Results 
Inhibition of eeZZ growth as measured by ceZZ counts, dye uptake and 
3H-TdR incorporation 
Fig. VIII shows that the amount of eluted dye is correlated to the 
number of cells. The correlation coefficient between cell number and 
eluted dye was 0.95. As little as 10,000 cells in a 6 em dish can be 
measured accurately. In our experimental conditions 
E550 of 0.1 corresponded with 7,500 RSb cells. 
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Fig. VIII. Correlation between number of ceZZs and E550 in dye 
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Fig. IX gives the results with the dye elution method and 3H-TdR 
incorporation in RSb cultures incubated with HFI. The two methods give 
similar results. 50 units of HFI reduced both the dye-uptake and the 
3H-TdR incorporation by 50%. 
CeZZ growth inhibition by interferon during conditions of viraZ in-
flammation 
Effect of viral challenge. The cells at the site of a viral infection 
are not only challenged with interferon, but also by the infecting 
virus. Table 20 shows the cell growth of RSb cells protected by inter-
feron and challenged by VSV. Viral challenge seemed to have no effect 
on the anticellular activity of interferon. 
Table 20. Influen~e of viral challenge on the inhibition of cell 
growth by HFI 
E550 of crystal violet eluted (SO) 
Control 1.688 (0.148) 
40 units HFI/ml 0.736 (0.069) 
40 units HFI/ml + 
104 CPE 050 VSV 
0.825 (0.082) 
104 CPE D5o VSV 0.052 (0.002) 
30 petri dishes were seeded with 125,000 cells/dish. In 20 dishes 
40 units of HFI were added. After 24 h in 10 dishes treated with 
HFI I04 CPE 050 VSV/dish were added. After 72 h of further incu-
bation cell growth was measured with the dye elution technique. 
Effect of mixtures of different types of interferon. During viral in-
flammation in vivo different types of cells may produce interferon. 
Cells will thus be challenged by different types of interferon. As it 
has been reported that interferon of one ·species can inhibit the 
action of interferon of another species, possibly by interaction at 
the cell receptor site (Chany, 1976), we tested the anticellular acti-
vity of different types of interferon added simultaneously. The results 
are shown in Table 21. Cell growth was inhibited for 40% by HLI (100 U) 
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and for 65% by HFI (100 U). When the interferons were added simulta-
neously, the growth inhibition was 80%. Therefore, any addition that 
may occur is only slight. 
Influence of temperature. Viral infections can cause a rise in body 
temperature and in local temperature by provoking an inflammatory 
reaction. Table 22 shows that the anticellular activity of HFI and 
especially HLI was enhanced by a rise in temperature. At 37° C the in-
hibition by 40 U of HLI was negligible, but at 39° C cell growth was 
reduced by more than 60%. 
Table 21. Growth inhibitory activity of HFI-HLI mixture 
Control (n = 5) 
100 units HLI/ml (n = 5) 
100 units HFI/ml (n =10) 
100 units HLI/ml + 
100 units HFI/ml (n =10) 
E550 of crystal violet eluted (SO) 
0.417 (0.090) 
0. 258 ( 0. 035) 
0.148 (0.036) 
0.074 (0.026) 
100,000 RSb cells were seeded in each petri dish and incubated 
with the indicated additions for 72 h. After incubation, cell 
growth was measured with the dye elution technique 
Table 22. Effect of temperature on the inhibition of cell growth 
by HFI a:nd HLI 
Temperature Contro 1 Treatment 
0.294 
0. 307 
0.244 
40 Ujml HFI 
0.138 (52%) 
0.126 (59%) 
0.037 (85%) 
40 U/ml HLI 
0.243 (16%) 
0. 216 (31%) 
0.093 (61%) 
RSb cells were seeded into 6 em petri dishes (100,000 cells/dish) 
and incubated for 72 h at 37°, 330 or 390 C (18 dishes at each 
temperature). 6 dishes of each group of 18 were treated with 40 U 
of HFI/ml, 6 dishes with 40 U of HLI/ml and 6 dishes were left un-
treated. After incubation, cell growth was measured with the dye 
elution technique. The mean extinction at 500 nm is shown with 
the percentage of growth inhibition in parentheses. 
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Discussion 
The measurement of cell growth inhibition of cells in monolayer by dye 
uptake and elution has a number of advantages: 
(1) it is not necessary to detach the cells from the surface on which 
they are cultured, a necessary step in other methods; 
(2) compared with cell counting, the dye elution method is quicker, 
more convenient and less sensitive to variables in and between tech-
nicians; 
(3) the dye elution method is also faster and more economical than the 
3H-TdR uptake technique; no special laboratory equipment or training 
in handling radioactive materials is needed. 
This study shows that the anticellular activity of interferon is not 
influenced by viral challenge or by simultaneous action of different 
types of interferon. Raising the temperature to 38° and 39° C even 
enhances the cytotoxicity. The biological significance of the cyto-
toxic effect of interferon is still obscure. It might be interpreted 
in several ways. Together with the specific inhibition by interferon 
of viral replication, inhibition of cell growth would result in an 
amplified antiviral effect. Another suggestion is that both the inhibi-
tion of viral replication and of cell growth are the result of the same 
molecular biological alteration in the cell. 
The primary function of interferon can be regulation of macro-
molecular processes and vi.ral replication probabiy has some character-
istics that make it very sensitive to this regulation. Therefore, the 
antiviral activity could just be a side-effect of the interferon sys-
tem and can be an explanation for recently published studies of inter-
feron in other conditions than viral infections (Gresser, 1977; 
Johnson, 1978; Trinchieri & Santoli, 1978; Trinchieri et al. 1978). 
65 
IN VIVO STUDIES 
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CHAPTER 5 
INTERFERON ADMINISTRATION IN CHRONIC HBsAg POSITIVE HEPATITIS 
The purpose of this study was to evaluate the efficacy of interferon 
in an otherwise untreatable disease. 
This study was achieved by cooperation of the Departments of Internal 
Medicine, Virology, and Pathology, Erasmus University Rotterdam, the 
Rega Institute, University of Leuven, Leuven, Belgium, the Central 
Public Health Laboratory, Helsinki, Finland, the Central Laboratory 
of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, the 
London School of Hygiene and Tropical Medicine, London, England, and 
Organon Scientific Development Group, Oss. 
This chapter is based on: 
'Fibroblast interferon in HBsAg positive chronic active hepatitis' by 
W.Weimar, R.A.Heijtink, S.W.Schalm, M.van Blankenstein, H.Schellekens, 
N.Masurel, V.G.Edy, A.Billiau & P. De Somer, published in Lancet II, 
1977, 1282; 
'Differential effects of fibroblast and leucocyte interferon in HBsAg 
positive chronic active hepatitis' by \LWeimar, R.A.Heijtink, 
S.W.Schalm & H.Schellekens, published in European Journal of Clinical 
Investigation 9, 1979, 151-154; 
'Double-blind study of leucocyte interferon administration in chronic 
HBsAg-positive hepatitis' by W.Weimar, R.A.Heijtink, F.J . .-P.ten Kate, 
S.W.Schalm, N.t.1asurel, H.Schellekens & K.Cantell, published in Lancet 
!, 1980, 336-338. 
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Introduction 
Liver cell damage in chronic hepatitis B surface antigen (HBsAg) posi-
tive hepatitis is probably the result of immunological action against 
hepatitis 8 virus-infected hepatocytes. Therefore, attempts have been 
made to treat this disease with immunosuppressive agents. Unfortunately, 
results of prednisone-azathioprine therapy were not encouraging (Schalm 
et al. 1976; De Groote et al. 1978). Another way of treatment is the 
elimination of the hepatitis B virus. In fact, eradication of the 
pachogenic organism is essential in all infectious diseases. However, 
until now this has not been accomplished in chronic H8sAg positive 
hepatitis with antiviral nor with immunoactivating agents as we have 
pointed out elsewhere (Weimar & Schellekens, 1979). 
In this chapter we describe the attempts to affect hepatitis 8 virus 
with interferon. To clarify our line of thinking we discuss these 
studies in chronological order. 
Initial Studies 
In 1976 it was reported that daily administration of 4 x 105 - 1 x 107 
reference units of HLI induced a rapid fall in hepatitis 8 core antigen 
(HBcAg) associated DNA polymerase (DNAP) in the sera of 3 patients 
(Greenberg et al. 1976). This enzyme activity is generally assumed to 
reflect the number of circulating Dane particles (the proposed hepa-
titis 8 virus). The suppressive effect on DNAP was transient when the 
interferon was given for 10 days or less, but appeared sustained for 
weeks after therapy in the 2 patients when treated for more than 1 
month. In addition, these 2 patients showed a drop in H8cAg titre and 
disappearance of hepatitis B 'e' antigen (H8eAg). One of them became 
permanently negative for HBsAg, HBeAg and DNAP (Greenberg et aZ.1979). 
Also in 1976 an effect of HFI was claimed in chronic HBsAg positive 
hepatitis (Desmyter et al- 1976). In the patient studied a decrease in 
the percentage of liver cell nuclei positive for HBcAg was observed 
after 7 injections of 10 7 reference units of HFI given on alternate 
days. H8sAg was not affected. 
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We studied the effect of HFI (Rega Institute, University of Leuven, 
Leuven, Belgium) and found no effect on hepatitis B virus indices. 
However, in 1 of our control patients a dramatic drop in DNAP was ob-
served. 
HFI IN HBsAg POSITIVE CHRONIC HEPATITIS 
Promising results of the effect of interferon therapy on indices of 
hepatitis B virus in HBsAg positive chronic hepatitis patients have 
been published (Desmyter eta~. 1976; Greenberg eta~- 1976) and edi-
torials have suggested a possible breakthrough in antiviral therapy 
(Editorial Lancet,1976; Ho, 1976; Zuckerman, 1976). Before attempting 
to eradicate hepatitis B virus by long-term interferon treatment and 
to determine the effect of elimination of the virus on the course of 
liver disease, we made dose-response studies with HFI under controlled 
conditions. 
4 patients (HBsAg positive for at least 6 months, aspartate amino 
transferase (AST) consistently more than twice normal, HBeAg positive, 
measurable DNAP activity) participated in our first study. 2 patients 
received HFI intramuscularly twice weekly, starting with 3 times 2 x 1cP 
reference units, followed by 3 times 4 x 106 reference units, and 
finally 3 times 8 x 106 reference units. No placebo preparations were 
administered in the 2 control patients. DNAP activity, HBeAg, HBsAg 
titre ('Hepatest'), AST and leucocyte counts were determined several 
times before, twice weekly during, and several times after treatment. 
No effect was observed on indices of virus activity in the interferon-
treated patients; 1 control showed a striking decline of DNAP activity; 
1 patient treated with interferon became leucopenic (Fig. X). 
To investigate the possibility that daily administration might be 
effective, 3 patients were given 3 x 106 reference units of HFI every 
day for 2 weeks. 3 other patients served as controls. Again, there was 
no effect on hepatitis B virus indices. 
It is possible that HLI is more effective than HFI or that indivi-
duals differ in responsiveness to interferon. However, evidence for 
the efficacy of interferon presented by others has come from uncontrol-
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led observations- a criticism made by Chalmers (1977) and with good 
reason, since we found that ONAP activity fell in a control patient. 
More evidence from dose-response studies in individual patients is 
needed before long-term treatment with interferon in a clinical trial 
is warranted. 
From this study we drew 2 conclusions: (a) we had to compare HFI with 
HL! and (b) all our studies should be properly controlled. Therefore, 
we decided to give HLI to the same patients who had received daily 
injections of HFI. The same dosage schedule was used and the same 
patients served as controls. 
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DIFFERENTIAL EFFECTS OF HFI AND HLI IN HBsAg POSITIVE CHRONIC HEPATITIS 
Introduction 
The therapeutic management of chronic hepatitis has improved markedly 
following the use of steroids and antimetabolites (Summerskill et aZ. 
1975). However, the benefits of this therapy are not striking in chro-
nic hepatitis associated with hepatitis B virus infection (Schalm et 
aZ. 1976). Recently, exogenous interferon has been claimed to modify 
indices of hepatitis B virus replication in patients with CAH (Desmyter 
et aZ. 1976; Greenberg et aZ. 1976). 
We have shown previously that twice-weekly administration of HFI did 
not have consistent effects on the indices of hepatitis B virus repli-
cation in chronic hepatitis. The possibilities remained, however, that 
daily injections could affect viral replication, or that HLI would be 
more effective than HFI. Therefore, we have evaluated the effects of 
daily HFI and HLI administration in patients with HBsAg positive chro-
nic hepatitis. 
Patients, Material and r~ethods 
We studied 6 patients who fulfilled the following criteria: HBsAg positive 
for at 1 east 1 year, positive for HBeAg and DNAP activity ,increased AST acti-
vi ty, norma 1 a1 fetoprotei n concentrations" 1 iver biopsy showing chronic 
active hepatitis, and no previous immunosuppressive therapy. Drs.M.van 
Blankenstein, R.A.Heijtink and S.W.Schalm helped us in selecting the 
patients and following their course. 
HFI was prepared at the Rega Insitute, University of Leuven, Leuven, 
Belgium, by a method described by Billiau et aZ.(1973). HLI was pro-
duced at the Central Public Health Laboratory, Helsinki, Finland, as 
described by Cantell et aZ. (1974). Both interferon preparations con-
tained approximately 106 reference uni ts/mg of protein, titrated in 
primary human fibroblasts with VSV as challenge virus and calibrated 
against the Medical Research Council 69/19 standard of HLI. 
In the first study 3 of 6 patients received 3 x 106 reference units 
HFI intramuscularly(i.m.) daily for2 weeks. In the second study 10 weeks 
later, the same 3 patients received 14 i.m. injections of 3 x 106 refe-
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renee units HLI; 2 patients daily for 2 weeks, the third patientwithin 
20 days. Control patients did not receive placebo injections. 
Blood samples were taken twice weekly for 2 weeks before and for 2 
weeks after interferon administration, and 3 times weekly during inter-
feron administration. Control patients were bled approximately weekly 
on several occasions before, during, and after the treatment periods. 
HBsAg was measured by radioimmunoassay with Ausria II (Abbott Labora-
tories) and positive sera were titrated by a reversed haemagglutination 
inhibition test (Hepatest, Burroughs Wellcome). HBeAg and anti-HBeAg 
were detected by double immunodiffusion. Reference sera were kindly 
provided by Dr. E. H. van El ven (Centra 1 Laboratory of the Netherlands Red 
Cross Blood Transfusion Service, Amsterdam). Identical results were 
obtained in 50 sera tested both in Amsterdam and in our laboratory. 
DNAP activity was determined as incorporation of 3H(dTMP) into an acid-
insoluble product by the method of Kaplan et aZ. (1973). Registered 
counts/min were only corrected for background radiation (approximately 
30 cpm). All sera from one patient were tested simultaneously; one 
serum of a healthy control was included in the test. For confirmation 
of our results, 15 different samples of concentrated serum were tested 
simultaneously by Dr.C.R.Howard (London School of Hygiene and Tropical 
Medicine, London, England) and by our laboratory with comparable 
results (r = 0.996; p < 0.001 Spearman rank correlation test). To test 
the specificity of the reaction for ONAP activity, a limited number of 
concentrated sera from all patients and controls were absorbed with 
sheep anti-HBsAg or normal sheep serum. After another absorption with 
rabbit anti-sheep serum, enzyme activities were not modified if the 
first absorption was performed with normal serum; in the case of ab-
sorption with anti-HBsAg serum, enzyme activities were lowered to the 
level of our normal control sera. Leucocytes (n: 3-10 x 109;1), plate-
lets (n: 150-450 x 109;1) and AST (n: 5-30 U/1) were measured by con-
ventional methods. AST (enzyme commission number: EC 2.6.1.1.) was 
measured using UV kinetic measurement technique at 340 nm in an LKB8600 
Reaction Rate Analyser at 35° C with 1-aspartic acid 125 mmol/1 in Tris 
buffer 40 mmol/1 as substrate at pH 8.0 (test combination Baker Labora-
tories, Deventer, The Netherlands). 
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Results 
Viral indices 
DNAP (Fig. XI). During HFI administration no patient showed a consis-
tent reduction of DNAP activity to less than pretreatment values (mean 
of 3 samples taken within 2 weeks before injections). During HLI admi-
nistration, a continued fall in DNAP activity was observed in all 3 
patients (-63%, -66%, -64%); after treatment DNAP activity rose to 
initial values in the 2 patients, but remained persistently(> 9 months) 
negative in 1 individual; DNAP activity remained high throughout the 
study in control patients. 
FIBROBLAST INTERFERON LEUCOCYTE INTERFERON 
treoted patient~ control patient$ !Tegted patients control patients 
pre first lost post pre first lost post pre first lost post pre first lost post 
week week week week week week week week 
Fig. XI. Mean DNAP activities 2 weeks prior to> dur-ing and 2 weeks 
after treatment with HFI and HLI preparations in HBsAg positive 
chronic hepatitis patients (upper limit of normal= 100 cpm). All 
patients were HBeAg positive during bOth study periods> except for 
patient e who became HBeAg negative ? weeks after HFI administration. 
HBsAg. HBsAg titres remained stable in all 6 patients during both HFI 
and HLI administration. 
HBeAg. During HFI administration all patients remained HBeAg positive. 
In 1 of these patients, however·, the HBeAg became undetectable 7 weeks 
after the first study. During HLI administration, the other 2 patients 
remained HBeAg positive. Contra 1 patients remained HBeAg positive 
during both study periods. 
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Liver function (Fig. XII) 
During HFI administration AST activities declined in all 3 patients 
(-29%, -37%, -45%) and returned to pretreatment values in the follow-
up period. 
During HLI administration AST activities declined in 1 patient from 
177 U/l to 78 U/1 and declined further in the follow-up period to 
30 U/l; no effect on AST activity was noted in the other 2 treated 
patients. 
Control patients showed no change in AST activities during both 
study peri ads. 
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Fig. XII. Mean AST activities 2 weeks prior• to~ _durinp:~ and 2 . 
weeks after treatment with HFI and HLI preparat~one ~n HBsAg pos~­
tive ehr•onic hepatitis patients (upper Zirrrit of normal= 30 U/lJ. 
Side effects 
In 1 patient a transient fall in leucocytes to 2.5 x 109;1 was observed 
during HFI administration; in the same patient HLI injections had to be 
stopped 5 times for 1 or 2 days because of leucopenia (1.4 x 109;1), 
mainly due to granulocytopenia (0.6 x 109;1). In another patient leuco-
penia was observed during HLI injections only (Fig. XIII). 
Chills and fever were noted in 1 patient during both studies and in 
another patient during HLI administration; promethazine was effective 
in prevention. No other side effects were observed. 
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Fig. XIII. Leueocytes 2 ~eeks prior to~ during~ and 2 weeks after 
treatment with HFI and HLI preparations in HBsAg positive chronic 
hepatitis patients (normal= 3-10 x 109/Z). 
Discussion 
Our results indicate that the effects of HFI and HLI in patients with 
HBsAg positive chronic hepatitis are different. HFI influences serum 
transaminase levels, an indicator of liver cell damage, while HLI seems 
mainly to affect DNAP activity, assumed to be a marker of circulating 
Dane particles. 
The effect of HLI on DNAP is in agreement with the results of Green-
berg et aZ. ( 1976). However, the sma 11 number of patients, the fl uc-
tuating levels of the enzyme activity, and its spontaneous decline in 
1 of our patients reported earlier must make us cautious in our inter-
pretation. The mechanism by which HLI affects only DNAP activity and 
not HBsAg titre is not clear. In most virus-cell systems, interferon 
acts at the post-transcriptional level (Friedman, 1977), where selec-
tive inhibition of translation may occur (l~iebe & Joklik, 1975). This 
could explain the discrepancy of the effect of interferon and DNAP 
activity and HBsAg in our patients. 
Immunoreactive mechanisms have been implicated in the cell destruc-
tion leading to elevated serum transaminase activities in chronic 
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hepatitis B infection (Eddleston, 1974). The decrease in transaminase 
levels by interferon in our patients could thus be explained by a 
direct immunosuppressive effect of interferon or by reduced expression 
of viral antigens on the liver cell membrane leading to a smaller num-
ber of targets for the immune apparatus. 
In this study the leucocyte count was affected more by HLI than by 
HFI. The rapid decrease (within 24 h) of leucocyte numbers, mainly 
granulocytes, in 1 of the patients makes a direct effect on bone marrow 
unlikely, and suggests redistribution or cytotoxicity for peripheral 
1 eucocytes. 
HFI and HLI are not identical. They differ not only in physico-
chemical properties (Cesario et al. 1977) and antigenic composition 
(Havell et al. 1975), but also in antiviral activity and cytotoxicity 
in certain cell systems (Edy et al. 1976; this thesis, chapter 4). 
l~olecules of human interferon may contain multiple active sites, and 
the number and distribution of these determinants are different for 
HLI and HFI (Paucker et al. 1975). Therefore, a different biological 
activity can be expected; this may account for the differential effects 
of HFI and HLI in this study. 
At present, only a limited amount of human interferon is available 
for small clinical trials. It is important to report observations 
such as these, so that the need for further production of both types 
of interferon for future studies may be assessed. 
Entracte 
~e partially confirmed the results of Greenberg et al.(1976). HLI in-
duced a fall in DNAP levels in the same patients in whom HFI proved 
ineffective. In 2 patients the effect on DNAP was transient; 1 patient 
remained DNAP-negative after the study. In these patients HBeAg became 
undetectable 7 weeks after HFI injections and 3 weeks before HLI admi-
nistration. Therefore, we did not know which (if any) interferon prepa-
ration had induced the complete disappearance of HBeAg and DNAP. In 
the other 2 patients HFI and HLI affected HBsAg titre and HBeAg. 
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Possibly, the dose of interferon was too small or the period of in-
jections was too short. 
In the meantime other groups reported their experience with inter-
feron in chronic HBsAg positive hepatitis. 
Kingham et aZ. (1978) treated 2 patients with 1 x 107 units HFI daily 
for 2 weeks. HBsAg titres did not fall; DNAP was not measured. An im-
mediate drop in anti-HBcAg titre was noted in both patients. This was 
difficult to interpret in view of the half-life of antibodies. It could 
be explained by an effect of interferon on the complement fixation 
reaction that was used to determine the anti-HBcAg titre. Such an 
effect has been described for HLI (Aha et aZ. 1976). In 1 patient with 
raised AST levels an initial increase in AST was seen followed by a 
return to pretreatment levels at the end of the second week of injec-
tions and normalization in the follow-up period. We did not find this 
effect in our patients. 
Scullard et aZ. (see Dunnick & Galasso, 1979) treated 8 patients with 
daily injections of 6 x 105 - 3 x 106 reference units HLI for periods 
from 5 to 9 weeks. 5 of these patients had measurable DNAP activity 
and all showed a fall during treatment. These 5 patients also showed 
a fall in Dane particle numbers. HBeAg disappeared in 2 of the 3 
patients in whom it was present. However, none of these. individuals 
developed a permanent change in Dane particle markers or HBsAg. In 
fact, these indices reverted to pretreatment levels in some patients 
while still on interferon. 
At an NIH meeting on clinical trials with interferon (April, 1978) 
Robinson showed the results of the Stanford group (see Dunnick & Galas-
so, 1979).They had treated 7 patients, including the 2 already reported 
(Greenberg et aZ. 1976) with daily injections of 4.2 x 105 - 1.2 x 107 
reference units HLI, for at least 1 month. In 2 patients all hepatitis 
B virus markers including HBsAg completely disappeared. In another DNAP 
and HBeAg became undetectable, while HBsAg remained present. In the 
other 4 patients partial reductions in circulating Dane particle mar-
kers were seen, but these changes reverted when the interferon injec-
tions were stopped. 
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Desmyter reported at the same meeting that 3 patients were treated 
with 3 x 106 reference units HFI daily for 1 week: 1 patient with 
1 x 107 reference units HFI daily for 1 week and 1 patient with daily 
injections of variable doses (1 x 105 - 1 x 106 units) HFI during 1 
month. No consistent changes in viral indices were found (see Dunnick 
& Galasso, 1979). 
Finally there was a report on 1 patient in whom DNAP, HBcAg and HBeAg 
disappeared during a 3-month course with daily injections of 1 x 106 
reference units HFI (Dolen et aZ. 1979); HBsAg remained detectable. 
In summary, data were available of 29 patients with chronic HBsAg 
positive hepatitis who had received interferon preparations. Only 1 of 
the 13 patients given HFI showed a permanent change of virus markers. 
A transient decrease in DNAP activity was the most consistent finding 
in the 19 patients treated with HLI. In 4 of them DNAP remained nega-
tive after treatment and 2 patients became in addition HBsAg negative. 
No control patients were involved in the studies by others. 1 of our 
control patients became DNAP negative. Dosage schedules varied consi-
derably within and between the different studies. Exact data on dose 
and duration of administration were not always obtainable. Neverthe-
less, we knew that 14 doses of 3 x 106 reference units HLI were not 
sufficient to affect DNAP activity definitely in all patients and we 
had the impression that interferon should be administered for at least 
1 month. 
We decided to perform a study in which we injected high doses HLI for 
a period longer than I month. We chose to start with 12 x 106 reference 
units daily for I week and halved this dose every week until disconti-
nuation after week 6. This dosage schedule was of course a long shot 
into the dark, but we were not aware of chronic HBsAg positive hepatitis 
patients who had been treated with higher dosages interferon for a 
longer time. 
Moreover, we had to be careful in view of the decrease in leucocyte 
counts that could be induced even with daily doses of 3 x 106 reference 
units HLJ. 
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DOUBLE-BLIND STUDY OF Hll ADf1INISTRATION IN CHRONIC HBsAg POSITIVE 
HEPATITIS 
Introduction 
In recent years human interferon preparations have been reported to 
affect indices of hepatitis B virus infections. In chronic HBsAg posi-
tive hepatitis, interferon was found to reduce HBcAg associated DNAP 
activity and HBeAg (Greenberg et aZ. 1976; Scullard et aZ., see Dunnick 
& Galasso, 1979; this chapter), HBcAg titre (Greenberg et aZ. 1976), 
anti-HBcAg titre (Kingham et aZ. 1978), Dane particle number (Scullard 
et aZ., see Dunnick & Galasso, 1979) and percentage of HBcAg-containing 
liver cell nuclei (Desmyter et aZ. 1976). In 2 patients all indices of 
hepatitis B virus infection, including HBsAg disappeared during inter-
feron treatment (Greenberg et aZ. 1979). However, none of these studies 
was properly controlled and the number of patients was small. Because 
indices of hepatitis B virus infection fluctuate, the only way to es-
tablish the value of interferon administration in chronic HBsAg posi-
tive hepatitis is a double-blind study. We report here the results of 
such a study, in which interferon was injected in higher dosages than 
previously reported (Greenberg et aZ. 1976; Desmyter et aZ. 1976; 
Kingham et aZ. 1978; Scullard et aZ., see Dunnick & Galasso, 1979; this 
chapter). 
Patients, ~laterial and Hethods 
16 patients (1 woman, 15 men) were studied who fulfilled the following 
criteria: HBsAg positive for at least 12 months, positive for HBeAg and 
HBc specific DNAP activity, abnormal levels of AST, but normal a1 fete-
protein, a1 anti-trypsin, caeruloplasmin and ferritin, and a biopsy 
showing chronic active hepatitis with positive HBcAg immunofluorescence. 
Patients were randomized to receive either HLI or placebo (human albu-
min). 
3 patients were on immunosuppressive therapy (prednisone and/or aza-
thioprine). The regimens were followed from 3 months before to 3 months 
after interferon administration. 
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HLI was prepared as described elsewhere (Cantell et aZ. 1974). It 
had an activity of 106· 4 reference units/mg protein, On an outpatient 
basis patients received 12 x 106 reference units i.m. during 1 week. 
Thereafter, the dose was halved every week until discontinuation after 
week 6, in an attempt to find an optimum dose for long-term therapy. 
On day 2 all 16 patients were vaccinated with an inactivated non-human 
influenza virus (Heq1Neq1) to allow the effect of exogenous interferon 
administration on a primary humoral immune response to be studied. 
None of the patients had detectable antibodies against this virus. 
Promethazine, 25 mg 3 times a day, was given to patients with fever. 
HBsAg titre was determined in a reverse passive haemagglutination 
test (Auscell, Abbott Laboratories). Anti-HBcAg was assayed with RIA 
(Corab, Abbott Laboratories) in serial dilutions of serum according to 
the manufacturer's directions. HBeAg was determined by the enzyme-
linked immunosorbent assay (ELISA) technique (Organon, Oss, The Nether-
lands) as described before (Van der Waart et aZ. 1978). DNAP activity 
was determined as incorporation of 3H(dH1P) into an acid-insoluble 
product as described before (Howard, 1978). Activity in negative con-
trol sera was 220 ~50 cpm (mean~ SD). The specificity of the reaction 
was confirmed by neutralization as described before (this chapter). 
HBcAg was tested by immunofluorescence technique on liver tissue from 
a biopsy specimen taken on the day after the last injection. Leucocyte 
and thrombocyte numbers and AST levels were determined with routine 
methods. For statistical analysis the Mann Whitney U test was used. 
Results 
After randomization no statistically significant difference was 
found between interferon and placego groups for age, estimated duration 
of illness, HBsAg titre, HBeAg titre, DNAP activity, AST levels, leu-
cocyte or thrombocyte counts (Tab 1 e 23). 
2 patients in the interferon group were on immunosuppressive therapy 
(1 patient 20 mg prednisone daily, the other 50 mg azathioprine daily). 
1 patient in the placebo group received 10 mg prednisone and 50 mg 
azathioprine daily. The only female patient in the study was in the 
interferon group. 
Tabte 23. Ctinicat and virotogicat indices of patients after randomization 
Interferon group (n=8) Placebo group (n=8) z va 1 ue 
median (range) median (range) 
Age 38 (25-60) 36 ( 20-53) 0.47* 
Duration of illness (years) 2.3 (1-5.5) 2.3 (1-6) o.oo* 
AST (U/1) 52 (24-76) 53 (29-138) 0.37* 
Leucocytes (x 109;1) 5.0 (3.9-7.6) 6.1 (4.7-11.2) 1. 21* (p ,_. 
Thrombocytes (x 109;1) 186 (155-267) 172 ( 139-271) 0.95* 
HBsAg titre - 1 12800 (1600-51200) 12800 (3200-51200) 0. 74* 
H8eAg titre (P/N ratio) 5.8 (4.5-11.1) 7.4 (5.0-14.4) 1. 37* 
DNAP (cpm) 2375 (284-3272) 725 (271-3759) 1. 58* 
j( p > 0.1 (~lann Hhitney U test) 
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Fig. XIV shows the DNAP activity in all patients. In the interferon-
treated group DNAP activity fell in 6 of 8 patients in the first week. 
The main drop in DNAP activity (median 65%, range 53-75%) occurred in 
these patients after the first 2 injections of 12 x 106 reference 
units (Fig. XV). Despite continuation of daily injections of this dose, 
no further fall was observed after day 4. In the placebo-treated pa-
tients DNAP activity fell between day 2 and day 4 (mean 32%, range 10-
60%) and returned to initial values on day 7. 
DNA Pol,....... ... 
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Fig. XV. DNAP levels during administration of 12 x 106 reference 
units of HLI. 
In 2 patients HBeAg titre paralleled the initial drop in DNAP acti-
vity. In the other 6 patients HBeAg titre was not influenced by inter-
feron administration. There was no effect on HBsAg titre or anti-HBcAg 
titre. Liver biopsy specimens taken on the day after the last injec-
tions showed positive HBcAg immunofluorescence in 30-70% (median 50%) 
Table 24. Changes in AST levels and leucocyte and thr>ombocyte counts in interfm•on and placebo groups. 
I niti a 1 t ~ day 7~ ~ day 14~ ~ day 21~ ~ day 28~ ~ day 35~ ~ day 42~ 
values 
AST 
(U/1) 
Interferon 52 +13 + 1 -11-+80 +25 +27 +44 
(24-76) (-16-+62) (-21-+46) (+4) ( -2-+178) ( 0-+209) (-9-+183) 
Placebo 53 -11 + 3 - 3-+31 +19 +20 +20 
(29-138) (-16-+29) (-16-+29) (+11) (+1- +38) (-3- +39) (-1-+102) 
Leucocytes 
(109/1) 
Interferon 5.0 -3.0+ -2.7+ -2.7+ -1. 9~ -1.6 -1.4 ro 
(3.9- 7.6) (-4.3--1.9) (-3.5--1.6) (-3.8--0.3) (-3.0--0.9) (-2.8-+0,1) (-3.9-+1.0) _,. 
Placebo 6.1 -0.3 -0.8 -0.4 +0.1 -0.6 -0.3 
(4.7-11.2) (-4.5- 0) (-3.7--0.2) (-2.7-+0.9) (-3.5-+1.4) (-4.3-+0.7) (-4.5-+0.3) 
Thrombocytes 
(109/1) 
Interferon 186 -63+ -49~ -18* -30* -22* +11 
(155-267) (-92--38) (-71-+3) (-94-+28) (-95-+31) (-48- +1) (-30- +68) 
Placebo 172 - 5 +42 +12 +48 +28 +78 
(139-271) (-19-+31) ( 0-161) (-12-+69) (-9-+138) (-12-+69) (+10-+175) 
~mean of 3 determinations bet\o1een day -14 and day 0; n = 8; median (range) 
+ n = 8; median (range) vs initial value 
~ p < 0.01 vs initial value and placebo 
p < 0.01 vs placebo 
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of liver cell nuclei in patients of the interferon group and in 35-85% 
(median 55%) in control patients. No statistically significant diffe-
rence was observed in AST levels between treated and control patients 
(Table 24). 
The vaccination procedure induced fever (38-39° C) in all 16 patient~ 
No interferon was detected in the sera from the control patients after 
vaccination. All patients responded with a rise in antibody titre to 
Heq1Neq1 virus. No difference was found in antibody levels between the 
2 groups after weeks 1, 2, 3 and 4. 
Late effects 
During the 3-month follow-up period all DNAP levels returned to initial 
values. In 1 patient of the placebo group, DNAP activity became unde-
tectable 3 weeks after the last injection. This was associated with a 
rise in anti-HBsAg and AST and a drop in HBeAg titre. 
Side effects 
Chills and/or fever (38-40° C) were noted in all 8 interferon-treated 
patients after the first injection only. 1 interferon patient had in-
creasing hair loss. A significant drop in leucocytes was seen during 
the first 3 weeks of interferon treatment. 6 out of 8 patients in the 
interferon group developed leucopenia (~ 2.5 x 109;1) during the second 
week. Thrombocytes were significantly lower than initial values after 
the first treatment week (Table 24). In none of the patients thrombo-
cytes dropped to values below 100 x 10911. 
Discussion 
Several studies have shown an effect of interferon administration on 
indices of hepatitis B virus infection in CAH. The most consisting 
finding has been a reduction in DNAP activity, which could be induced 
by injections of between 4 x 105 and 3 x 106 reference units of HLI 
(Dunnick & Galasso, 1979). 
Also in this study, we found a drop in DNAP activity after the first 
injections of interferon. Thereafter, no further fall was observed, 
despite continuation of daily injections of 12 x 106 reference units 
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during the first week. The results of interferon administration in the 
2 patients on immunosuppressive therapy (1 woman, 1 man) were the same 
as in the other patients. In tbis randomized study we could not confirm 
effects of interferon on other indices of hepatitis B virus infection 
that have been reported before, such as HBsAg titre (Greenberg et aZ. 
1976), HBeAg (Greenberg et aZ. 1976; Scullard et aZ., see Dunnick & 
Gal as so, 1979; this chapter) and anti -HBcAg titre (Kingham et aZ.1978). 
Interferon administration had no effect on the number of liver cell 
nuclei positive for HBcAg. AST was not affected. Interferon had no ef-
fect on the primary immune response to an inactivated non-human influ-
enza virus (Heq1Neq1). 
In an earlier report on interferon administration in HBsAg positive 
chronic hepatitis we described a control patient who became DNAP-nega-
tive during the study. In the present study, too, DNAP activity became 
undetectable in 1 patient after placebo treatment. This makes uncon-
trolled observations of the efficacy of interferon in individual pa-
tients with HBsAg positive chronic hepatitis difficult to interpret. 
The effects of interferon are complex and poorly understood (Gresser, 
1977; Friedman, 1977; this thesis). It can inhibit viral multiplica-
tion in vivo both directly and through the host. The drop in DNAP acti-
vity in the beginning of interferon administration could be mediated by 
the host, e.g. by the raised body temperature on the synthesis of com-
plete Dane particles. The vaccination-induced fever was also associated 
with a fall in DNAP activity in our control patients. No further fall 
in DNAP was noted after the temperature had returned to normal at the 
end of the first week of interferon treatment. 
We used higher dosages of interferon than reported before (see 
Dunnick & Galasso, 1979). This resulted in leucopenia in 6 of the 8 
patients during the first 2 weeks. Therefore, continuation of daily 
injections of high doses of interferon or increasing the dose might not 
be possible. 
In conclusion, the only effect of interferon administration in chro-
nic HBsAg positive hepatitis was a transient reduction in DNAP activi-
ty, without apparent clinical significance. On the basis of these 
findings, long-term treatment of this disease with HLI alone does not 
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look promising. However, the other dosage schedules might perhaps be 
effective e.g., intermittent interferon administration, a gradual in-
crease of the dose, or a combination with other therapies. 
Conclusion 
In this chapter we have reviewed the available literature on interferon 
administration in chronic HBsAg associated hepatitis. We have shown our 
attempts to eradicate the hepatitis B virus with different dosages HFI 
and HLI. 
In our opinion, curing patients with chronic HBsAg positive hepatitis 
with interferon alone is not possible. 
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CHAPTER 6 
DOUBLE-BLIND STUDY OF INTERFERON ADMINISTRATION IN 
RENAL TRANSPLANT RECIPIENTS 
The purpose of this study was to evaluate the prophylactic activity of 
interferon in a patient group highly susceptible to viral infections. 
This study was achieved by cooperation of the Departments of Internal 
Medicine, Virology, and Surgery, Erasmus University Rotterdam, and the 
Rega Institute, University of Leuven, Leuven, Belgium. 
This chapter is based on: 
'Double-blind study of interferon administration in renal transplant 
recipients' by W.Weimar, H.Schellekens, L.D.F.Lameijer,. N.~1asurel, 
V.G.Edy, A.Billiau & P. De Somer, published in European Journa~ of 
C~inica~ Investigation 8, 1978, 255-258. 
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Introduction 
In animal models interferon exerts its clearest effect when given to 
prevent viral infections (Finter, 1973). For this reason human inter-
feron might be expected to be useful when acute viral infections are 
likely to occur. This is the case after renal allograft transplanta-
tion. 
Table 25 shows the viral infections diagnosed in renal transplant 
recipients in Rotterdam from June 1973 until July 1975. In thi_ period 
48 patients received a renal allograft and 43 of them were followed 
for at least 3 months. Neither attempts to isolate viruses nor serolo-
gical tests were performed on a ,regular ,basis. In 34 patients ade-
quately screened for viral infections, 59 positive diagnoses were made 
in 32 patients. 
TahZe 25. Number of viral infections in renal transpZant recipients 
in Rotterdam, June 1973 to JuZy 19?5. 
< 3 months > 3 months Total 
after transplantation after transplantation 
HSV 17 4 21 
CMV 15 2 17 
EBV 1 1 2 
33 7 40 
Rubella 2 3 5 
Parainfluenza 0 4 4 
Influenza A 1 2 3 
Influenza B 0 1 1 
RSV 2 2 4 
Adenovirus 1 1 2 
6 13 29 
Total 39 20 59 
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Table 26. Viral infections in renal allograft recipients 
Herpetoviridae* 
Reference No.of patients CMV HSV vzv EBV 
Craighead eta~. (1967) 41 73 
Simmons et a~. (1974) 132 74 26 5 
Balfour eta~. ( 1977) 28 64 54 18 
Pass et a~. (1978) 40 92 70 
Fiala et a~. (1975) 35 96 35 24 0 
Koranda et aZ. (1974) 200 35 13 
Armstrong et a~. (1976) 23 43 38 32 
Andersen & Spencer (1969) 36 91 
Rytel & Salay ( 19 76) 41 90 
Strauch et a~. (1974) 21 56 
Pien et a~. (1973) 17 59 53 35 
Betts et aZ. (1975) 54 63 
Papovaviridae* 
Reference No.of patients BK Papi 11 oma ~arts) 
Co 1 eman et aZ. ( 1973) 74 38 
Koranda et a~. (1974) 200 43 
Shah et aZ. (1974) 17 18 
Lecatsas et a~. (1973) 17 
"' numbers denote % of eatients 
Table 26 shows the incidence of viral infections in renal transplant 
recipients in different centres. ~lost of these infections occurred in 
the first 3 months after transplantation and were caused by members of 
2 groups of DNA viruses: Herpetoviridae : herpes simplex (HSV), cyto-
megalovirus (CMV), varicella zoster virus (VZV) and Epstein-Barrvirus 
(EBV); and Papovaviridae: BK virus, papilloma (warts) virus. 
Apart from producing clinical viral disease, viral infections can 
modulate the immune system. Further immunosuppression can predispose 
to superinfections (Rubin et aZ. 1977), while immunostimulation may 
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lead to graft rejection (Simmons et al. 1974). Moreover, viruses may 
be involved in oncogenesis, leading to the high incidence of malignant 
tumours in renal allograft recipients (Matas et aZ. 1975; Penn, 1975). 
In this chapter we describe our attempt to control viral infections 
in renal allograft recipients with HFI. We injected a dose of HFI com-
parable to the amount of HLI claimed to be effective in reducing viral 
infections (Strander et al. 1976). 
Patients, Material and Methods 
Interferon preparations 
Interferon preparations were produced in human embryo fibroblasts by 
the method described by Billiau et al. (1973), modified by Edy (Edy et 
al. 1976; Edy, 1977). The interferon was titrated by inhibition of VSV 
replication in human diploid cells using a dye uptake method, and was 
calibrated against the Medical Research Council 69/19 standard of HLI. 
The approximate activity, before addition of human serum albumin as a 
stabilizer, was 104· 7 units/mg of protein. Placebo preparations were 
dilutions of human plasma protein fraction (Belgian Red Cross), con-
centrated and fractionated with the same techniques as the crude inter-
feron preparations. 
Patients 
The study group consisted of 18 patients who received their renal 
transplants in the University Hospital Rotterdam-Dijkzigt from February 
1976 to April 1977. All non-diabetic, HBsAg-negative patients between 
18 and 45 years of age were included. The immunosuppressive regimen 
consisted of prednisone (35 mg daily) and azathioprine (1-2 mg/kg 
daily). During acute rejection episodes the dose of prednisone was 
increased. 
The study was set up in a double-blind, placebo-controlled fashion, 
in consecutive pairs to avoid seasonal influences, and to assist in 
early detection of possible side-effects of interferon therapy. In each 
pair the patients received either placebo or interferon (3 x 106 U) 
i.m. twice weekly for 3 months, starting 1-2 h before transplantation. 
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Blood samples for haematology were taken daily during the first month 
after transplantation and twice weekly for the following 2 months. 
Blood samples for virus serology and liver function parameters were 
taken weekly during the first 3 months and twice monthly in a 3-month 
follow-up period. 
ViraZ diagnosis 
Antibodies to influenza virus A and B, adenovirus'· respiratory syncy-
tial virus (RSV), measles virus, CMV (A0-169 strain), HSV, VZV, para-
influenza viruses I, II and III, polio viruses I, II and Ill, MyeopZasma 
pneumoniae and Chlamydia psitaeei were determined by the complement 
fixation (CF) test by a microtitre technique according to Lennette 
(1969). Antibodies to rubella virus were measured by the haemagglutina-
tion inhibition (HI) test, heterophile antibodies by the method ofPaul-
Bunne 11 , and HBsAg and anti -HBsAg by radioimmunoassay. Seri a 1 specimens 
from each patient were tested simultaneously. A fourfold or greater in-
crease in antibody titre within 2 weeks was considered to be serological 
evidence of infection. As prevention of clinical illness was our main 
interest, viral isolations were performed only if a viral infection was 
suspected on clinical grounds. 
Results 
Table 27 shows the incidence of viral infections in both the interferon 
and placebo groups. Significant rises of CF antibody titres for CMVwere 
seen in 9 of the 18 patients studied (50%). 5 were in the interferon 
group, 4 in the control group. 5 of these 9 patients were initially CF 
seronegative for CMV. In 2 patients of the interferon group and 1 ofthe 
control group this seroconversion was related to an episode of fever 
(> 38° C, for more than 2 days) and thrombocytopenia (< 100 x 109;1). In 
one patient of the interferon group this episode was accompanied by he-
patitis, mononucleosis, leucopenia (< 2.5 x 109;1), and CMV shedding in 
the urine, and was considered life-threatening. 
5 patients (31%) ·showed serological evidence of HSV infection. 2 of 
them were originally CF seronegative. 4 were in the placebo group and 1 
Table 2?. Vir-al infections 
Interferon group 
Viral infections lt 2 3 
CMV Serological - + -
Clinical u 
- - -
HSV Serological - - -
Clinical - - -
vzv Serological - - -
Clinical 
Influenza A Serological + 
Clinical + 
Rubella Serological - - -
Clinical - - -
RSV Serological - - -
Clinical 
Viral infections serological +clinical 
Viral infections serological only 
No. of patients with viral infections: 
Serological + clinical 
Serological only 
4 
-
-
-
-
-
+ 
+++ 
-
5 
+ 
+++ 
-
-
-
-
-
-
5 
6 
5 
2 
6 7 
- + 
- -
- + 
- + 
- -
- -
- -
8 9 
+ + 
- + 
- -
- -
+ 
+ -
+ 
1 2 
- + 
- -
t + 
++ ++ 
- -
~ Numbers denote patient pairs 
Clinical infections graded as+ : minor;++ : serious; +++ : very serious 
3 
-
-
-
-
-
Placebo group 
4 
+ 
-
-
-
-
5 
-
-
-
-
-
4 
5 
4 
2 
6 
+ 
+ 
-
-
-
7 8 9 
- + 
+ + 
- ++ 
<D 
- + 
..,. 
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in the int~··feron group. An extensive and painful eruption involving 
the facial skin and/or oral mucosa was seen in 3 patients of the pla-
cebo group. The patient in the interferon group showed only a minor 
herpes labialis. Virus isolations were positive in all 4 cases of her-
pes eruptions. 
3 patients with positive antibody.titres for rubella before trans-
plantation showed significant HI titre rises. 2 of them were in the 
interferon group, 1 in the placebo group. In 1 patient of the interferon 
group this seroconversion was accompanied by a meningo-encephalitis 
that was considered on clinical grounds to be of viral origin. 
1 clinical case of influenza-like illness was seen in the interferon 
group. It was associated with seroconversion to influenza virus. In 
another interferon-treated patient we found serological evidence of 
rubella virus, RSV, CMV and VZV infections. These seroconversions were 
not related in time and no clinical viral infections were evident. No 
significant changes in CF antibody titres were noted in any patient for 
the other viruses that were tested for. All viral infections occurred 
in the 3 months after transplantation. No viral infections were diag-
nosed in a 3-month follow-up period. 
In summary, a total of 5 clinical viral infections were observed in 
5 patients of the interferon group. In the placebo group 4 patients 
with clinical viral infections were seen. On serological grounds 6 sub-
clinical infections occurred in the interferon group and 5 in the pla-
cebo group. No difference was found in the number of patients for whom 
only serological evidence was found for viral infection (2 in each 
group). 
Table 28 shows the number of episodes (~ 2 days) of leucopenia, 
thrombocytopenia, elevated transaminases as well as acute rejection for 
both the interferon and placebo group. Patients in the interferon group 
had slightly fewer episodes of leucopenia, thrombocytopenia, and acute 
rejection. No difference was found in the number of episodes in which 
serum transaminase levels were raised. Pain at the injection site was 
not reported. In 2 patients febrile reactions were noticed after intra-
muscular adminis~ration of interferon, with temperature rises up to 
38° c. 
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Table 28. Haematology~ liver function parameters~ and acute re-
jection episodes 
Leucopeniat (< 2.5 x 109;1) 
Thrombocytope;iat (< 100 x 109;1) 
Raised AST t ( > 35 IU/1) 
Raised ALTt~(~ 35 IU/1) 
Acute rejection 
~ numbers denote episodes of > 2 days 
ALT = alanine aminotransferase 
Discussion 
Interferon 
group 
2 
3 
4 
6 
13 
Placebo 
group 
3 
5 
4 
6 
16 
Systemic administration of HLI has been used in clinical trials for the 
therapy of herpes zoster (Strander et aZ. 1973; Emodi et aZ. 1975; 
Merigan et aZ. 1978), serious CMV infections (Arvin et aZ. 1976; Emodi 
et aZ. 1976; O'Reilly et aZ.1976) and HBsAg-positive chronic hepatitis 
(Greenberg et aZ. 1976; Desmyter et aZ. 1976; this thesis, chapter 5). 
Only in herpes zoster suggestive evidence for successful treatment has 
been reported. In animal studies interferon appeared to be effective 
when given prophylactically or early in the course of viral infection. 
Evidence for the prophylactic value of systemic HLI administration in 
man was suggested by Strander et aZ. (1976) and Ahstrom et aZ. (1974), 
who reported a significant lower incidence of symptoms of common viral 
infections in patients given interferon in the treatment of osteosar-
coma and leukaemia. 
In the present study we have evaluated the prophylactic effectiveness 
of HFI in a double-blind trial in renal transplant recipients. HFI 
injections were tolerated well by our patients. No evidence was found 
for an adverse effect on bone marrow, liver or renal transplant. Our 
results indicate that HFI given twice weekly i .m. in a dose of 3 x 106u 
is not capable of reducing the number of clinical and subclinical viral 
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infections in renal allograft recipients. Severe herpes simplex infec-
tions occurred only in the placebo group, but the difference from the 
interferon group was not statistically significant. Clinical symptoms 
of cr~V and rube 11 a virus infections were more severe in i ndi vi dua 1 
patients in the interferon group. 
Several possibilities arise to explain the apparent lack of effect of 
interferon in our trial. It could be due to the immunodepressed state 
of our patients, although it has been reported that interferon might be 
effective under these circumstances (Neumann-Haefelin et aZ. 1976). 
Alternatively, the dosage of interferon we used could have been in-
sufficient, although Strander et aZ. (1976) suggested that a comparable 
dosage of HLI can protect against viral infections. 
Finally, HFI could be less active than HLI. Recently it has been 
shown that these two interferon preparations are equally effective in 
the treatment of herpetic keratitis (Neumann-Haefelin et aZ. 1977). 
However, nothing is known about the comparative efficacy of systemic 
administration of these interferons. In conclusion, it would seem that 
the possible slight.benefits that may accrue from administration of 
this dosage of HFI in renal transplant recipients are outweighed by 
the technical and economic problems of interferon production for larger 
trials. It remains to be demonstrated whether other types of interferon 
may be more effective in this group of patients. 
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CHAPTER 7 
THE EFFECT OF HUMAN INTERFERON ON VACCINIA VIRUS INDUCED SKIN 
LESIONS IN RHESUS MONKEYS 
The purpose of this study was to find an optimum dosage schedule for 
systemic administration of human interferon by use of a monkey model. 
This study was achieved by cooperation of the Departments of Virology 
and Internal Medicine, Erasmus University Rotterdam, the Virology 
Section of the Primate Centre TNO, Rijswijk, the Rega Institute, Uni-
versity of Leuven, Leuven, Belgium, and the Central Public Health 
Laboratory, Helsinki, Finland. 
This chapter is based on: 
'Antiviral effects of interferon in vivo may be mediated by the host' 
by H.Schellekens, W.Weimar, K.Cantell & L.Stitz, published in Nature 
278, 1979, 742; 
'Prevention of vaccinia lesions in rhesus monkeys by human leucocyte 
and fibroblast interferon' by W.Weimar, L.Stitz, A.Billiau, K.Cantell 
& H.Schellekens, to be published in Journa~ of Genera~ Viro~ogy, 1980. 
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General Introduction 
Interferon is being evaluated clinically in a number of institutes and 
in a wide variety of diseases. Dosage schedules vary along with the 
institutes and the diseases and seem more related to the amount of 
interferon the clinicians can get hold of than to sound experimental 
data. To provide these experimental data we studied the effect of 
human interferons in rhesus monkeys on the development of skin lesions 
after intradermal infections with vaccinia virus. If human interferon 
could influence the development of these lesions it would mean a non-
mutilating, easy-to-score, primate model to study problems like dose-
response relations, timing of interferon administration, relation of 
in vitro and in vivo activities, toxicity, etc. 
The intradermal vaccinia infection has a longstanding reputation in 
interferon research. The first in vivo experiments both in animals and 
in man studied the effect of local interferon administration on the 
subsequent take of intradermal vaccinia infections. They showed that 
exogenous interferon had an antiviral effect in vivo. 
In the first part of this chapter we describe the effect of systemic 
interferon administration on vaccinia infection. It concerns the dose-
response effect of HLI, the relative efficacy of HLI and HFI and the 
influence of route of administration. 
In the second part the in vitro activity of HLI against vaccinia 
virus is compared with the in vivo effect. 
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PREVE~TIO~ OF VACCINIA LESIONS IN RHESUS MONKEYS BY HLI AND HFI 
Introduction 
In recent years evidence has been accumulating for the effectiveness of 
systemic interferon administration in the treatment of both viral and 
neoplastic diseases in man (Dunnick & Galasso, 1979). Treatment sche-
dules in different studies vary considerably: clearly the optimum dose 
and frequency and route of administration are not known. High doses of 
interferon are found to be necessary to influence the course of an es-
tablished viral infection (Merigan et aZ. 1978). Less interferon may 
be needed for prevention of viral disease. However, results of studies 
on the prophylactic efficacy are conflicting (Strander et aZ. 1976; 
Cheeseman et aZ. 1979; this thesis, chapter 6). 
The interferon preparations used so far for c·linical stuofes have 
been derived from two sources: human leucocytes induced with Sendai 
virus (HLI) and human diploid fibroblasts induced with double-stranded 
RNA (HFI). Little is known of the comparative efficacy of these prepa-
reations. When applied topically, no difference was found in the effect 
on herpes keratitis (Sundmacher et aZ. 1978). Used systemically in 
HBsAg-positive chronic hepatitis, differential effects of these inter-
ferons were reported (This thesis, chapter 5). 
In an attempt to determine an optimum treatment regimen and to 
clarify possible differences in the efficacy of these interferon pre-
parations, we have performed dose-response studies with HLI and com-
pared the activity of HLI and HFI in rhesus monkeys inoculated intra-
dermally with vaccinia virus. It has been reported that relatively 
crude interferon preparations can suppress vaccinia lesions in monkeys, 
whether injected intradermally or intravenously (Andrews, 1961; Pinto 
etaZ. 1970). 
Material and ~1ethods 
Virus 
The source, propagation, and titration of vaccinia virus (RIV strain) 
have been described elsewhere (Hekker et aZ. 1973). 
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Animals 
Rhesus monkeys (Macaca mulatta) bred at the Primate Centre TNO (Rijswijk, 
The Netherlands) and weighing 1.5 to 3 kg were employed. Only animals 
lacking antibodies to vaccinia virus, as tested by a serum neutralisa-
tion test, were used. 
Interferons 
HLI was prepared as described before (Cantell et aZ. 1974) and had an 
activity of 106·2 units;mg protein. HFI, prepared and partially puri-
fied as described elsewhere (Billiau et aZ. 1979), had an activity of 
106·0 units/mg protein. 
Interferon titration 
Interferon activity was measured with a dye uptake method, employing 
diploid skin fibroblasts and VSV as a challenge virus (Finter, 1969); 
units refer to the standard of HFI (G-023-902-527) provided by the 
National Institutes of Health (Bethesda, Md., USA). Interferon activity 
was also determined by a cytopathic effect inhibitory assay, employing 
RSb cells and VSV as a challenge virus; units refer to the standard of 
HLI (Medical Research Council 69/19). 
Experimental design 
Animals were kept in quarantine from 2 weeks before the start until 2 
weeks after the experiments. Interferon was injected daily, starting on 
the day before vaccination until 7 days after vaccination. Each monkey 
was inoculated on the chest by intradermal injection of 0.05 ml al iquots 
of live vaccinia virus at different concentrations (107, 106 and 105 
TCIDso/ml-1), UV- inactivated and heat-inactivated virus (107 TCID50; 
ml-1 before inactivation) and saline. 
Each virus dilution and all controls were injected at 3 sites. Ani-
ma 1 s were kept under genera 1 anaesthesia during vaccination. The monkeys 
were examined daily and the skin lesions were scored by 2 independent 
observers on an arbitrary scale from 0 to 4, based on appearance and 
severity of papules and pustules. Each day one third of the animals in 
turn were anaesthesized to allow photographic recording of the lesions 
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as well as blood sampling for various tests. Blood samples were taken 
3 to 4 hours after the first interferon injection. 
Results 
In the first experiment groups of 3 monkeys received i.m. injections 
of either saline or 5 x 105 units/kg HFI or HLI. Typical vaccinia skin 
lesions developed in all untreated monkeys: pustules appeared between 
day 4 and day 7 after infections. All virus dilutions induced these 
lesions, while no lesions were produced by inactivated virus or saline. 
All 3 monkeys treated with HLI and 1 monkey treated with HFI were com-
pletely protected against vaccinia virus. In the 2 other animals in-
jected with HFI, the pustules were smaller than in the control animals. 
In the protected monkeys, no vaccinia lesions developed after discon-
tinuation of interferon treatment during the observation period of 42 
days. 
In the second experiment 3 groups of 3 animals were given different 
dose schedules of HLI i.m. (5 x 105, 1.25 x 105 and 0.5 x 105 units/kg, 
respectively); a control group received i.m. injections of saline. All 
control animals developed vaccinia lesions. The highest dose of HLI 
protected 2 monkeys completely; the other two dosage regimens inhibited 
formation of pustules in 1 monkey of each group. Lesion size appeared 
to be influenced by the dosage of interferon. Fig. XVI shows the inhi-
bition of lesion scores in monkeys treated with different doses ofHLI. 
In the third experiment 2 groups of 3 monkeys received HLI (5 x 105 
units/kg) i.m. or intravenously (i.v.); 2 other groups received HFI 
(5 x 105 units/kg) i.m. or i.v.; again a control group received i .m. 
injections of saline. The 3 control monkeys developed pustules. All 
animals treated with HLI, whether by i.m. or i.v. route, were protected. 
All monkeys treated with HFI i.m. were equally well protected. I.v. 
given HFI depressed lesion size in 2 monkeys, while 1 monkey was com-
pletely protected. Fig. XVII shows the inhibition of skin lesions in 
monkeys treated with HFI given by different routes. 
Serum interferon levels 3 h after i.m. injections are shown in Table 
29. Similar levels were found after injections of HLI, whether the sera 
were assayed on diploid skin fibroblasts against the HFI standard or on 
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Fig. XVI. Skin lesion scores in rhesus monkeys treated i.m. with 
HLI: • • controls (n = 6); o----odaily dose 0. 5 x 105 
units/kg (n = 3); o----o daily dose 1.25 x 105 units/kg (n=3); 
.. ----... daily dose 5 x 105 units/kg (n = 6). Interferon was 
injected from 1 day before to 7 days after vaccinia infection. 
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Fig. XVII. Skin lesion scores in rhesus monkeys treated with 
5 x ]0.5 units/kg HFI: • • controls (n = 6); l:r-----:6. i.v. 
route (n = 3); o------o i.m. route (n = 6). Interferon was 
injected from 1 day before to 7 days after vaccinia infection. 
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TabZe·29. Levels of serum interferon and vaccinia lesion seore in 
rhesus monkeys treated with human.interferons 
~~ Dose Serum interferant Mean lesion score (units/kg) (units/ml) on day 6 
HLI 5 X 105 250 0.7 
1.25 X 105 120 2.2 
0.5 X 105 80 3.0 
HFI 5 X 105 140 1.3 
Control <~ 4.0 
t Blood samples taken 3 h after i.m. injection; average values of 
3 animals; interferon activity assayed on diploid fibroblasts 
against HFI standard 
a continuous cell line (RSb cells) against the HLI standard. Afteri.m. 
injections of HFI, interferon activity in the sera was detected only 
when the assay on diploid fibroblasts was used. Table 29 shows that 
injections of 5 x 105 units/kg of HFI resulted in serum levels compa-
rable with those after HLI given in a dose of 1.25 x 105 units/kg. 
Furthermore, these doses were about equally effective in reducing le-
sion scores. 
Discussion 
The present study shows that i.m. administration of either HLI or HFI 
can protect rhesus monkeys against vaccinia virus induced skin lesions. 
With HLI, the development of lesions was suppressed with all 3 dose 
regimens used: 5 x 105, 1.25 x 105 and 0.5 x 105 units/kg. However, 
only the highest dose was capable of completely suppressing lesions. 
From this it would appear that the corresponding dose for man would 
be approximately 30 x 106 units daily. 
From the studies described in the second part of this chapter it 
would seem that the direct antiviral effect of interferon on cells does 
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not play the main role in the in vivo protection of monkeys against 
vaccinia virus. In vitro, the monkey cell/vaccinia virus system is 
virtually insensitive to both HFI and HLI. Therefore, it can be pro-
posed that the effect against vaccinia virus in monkeys results from 
the activation of host defence mechanisms other than interferon, such 
as NK-cells or macrophages. It may well be that lower doses would be 
sufficient to provide in vivo protection in those host/virus systems 
where the direct effect of interferon on viral replication does play an 
important role in limiting initiation or progression of disease. In 
patients with malignancies treated with 3 x 106 units of HLI 3 times a 
week, the incidence of symptoms of viral infections was reported to be 
reduced (Strander et al. 1976). In general, higher dosages are probably 
needed if therapy is started after appearance of symptoms of viral in-
fections. The dose of HLI necessary to suppress lesions completely in 
our vaccinia/monkey model roughly corresponded with that necessary to 
influence the course of varicella or herpes zoster in patients (Arvin 
et al. 1978; Merigan et al. 1978). 
One can hypothesize that in a therapeutic, as opposed to prophylactic 
situation, the direct effect of interferon on viral replication is of 
less importance. Therapeutic effects may result mainly from activation 
of other host-defence mechanisms which require higher doses of inter-
feron. The prevention of vaccinia virus induced skin lesions was not 
dependent on the amount of virus inoculated. Lesions appeared at seve-
ral inoculation sites with different virus doses or not at all; lesion 
sizes correlated inversely with the dose of interferon. This is in line 
with our hypothesis that interferon does not exert its action by inhi-
biting virus replication, but rather by activating host-defence mecha-
nisms. This hypothesis could explain why interferon is not fully effec-
tive in immunocompromised patients (Cheeseman et al. 1979; this thesis, 
chapter 6). 
HFI inhibited lesion development in much the same way as HLI. Quan-
titative comparisons between the effects of these 2 interferons must 
take into account that they are 2 different molecules with different 
host ranges and different dose response curves in vitro (Edy et al. 
1976). In the vaccinia/monkey model the effect of 5 x 105 units/kg of 
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HFI was about the same as that of 1.25 x 105 units/kg of HLI. Thus, on 
the basis of nominal units, HFI was about 4 times less effective than 
HLI. One could explain this difference by the fact that i.m. injected 
HFI results in lower blood titres than HLI (Edy et aZ. 1978). Recent 
evidence indicates that HFI is inactivated at the i.m. injection site 
(W. E. Stewart, persona 1 communication). In our experiments, the group of 
HLI-treated and HFI-treated monkeys with comparable protection also had 
comparable blood titres. Thus, our experiments indicate that quite high 
serum levels are a requirement for interferon to be active against 
vaccinia virus in vivo. 
In order to circumvent the problem of insufficient absorption ofHFI, 
1 group of monkeys was given HFI by the intravenous route. These mon-
keys were also partially protected, but less so than monkeys given the 
same dose by the i.m. route. It is known that i.v. injected interferon 
is rapidly cleared from the circulation. Therefore, while this proce-
dure ensures that all interferon reaches the blood stream, it also may 
allow too little time for HFI to activate host-mediated mechanisms. 
The Scientific Committee (1970) reported that the insensitivity of 
vaccinia virus to interferon in vitro discouraged their plans to modify 
this infection by systemic interferon administration. In our opinion, 
this i nsens iti vi ty pro vi des an interesting mode 1 to study the anti vi ra 1 
mechanisms by which interferon acts in vivo. Treatment regimens infer-
red from this model may also give some guidelines for the treatment of 
patients with interferon. However, the limitations of this model must 
also be kept in mind, and the crucial comparisons between HLI and HFI 
will have to be done in clinical trials. 
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ANTIVIRAL EFFECT OF INTERFERON IN VIVO MAY BE MEDIATED BY THE HOST 
Introduction 
Interferon has antiviral effects both in vivo and in vitro. Viral re-
plication is inhibited in interferon-treated cells in vitro because the 
reproductive cycle of the virus is inhibited at the transcriptional or 
translational levels, depending on the virus-cell system studied 
(Friedman, 1977). This direct inhibition of viral replication has been 
assumed to also be the mechanism by which interferon exerts its anti-
viral effect in vivo. We report here results that indicate protection 
by interferon against viral infection in vivo without inhibition of the 
viral replication of the same virus in vitro. 
Material and Methods 
To test the antiviral effect of HLI in vivo, 6 rhesus monkeys were in-
fected intradermally with vaccinia virus, strain of the RIV, described 
before by Hekker et aZ. (1973). They were vaccinated on day 0 with the 
following preparations: 107 TCID50ml-
1 vaccinia virus; 106 TCID50ml-
1 
vaccinia virus; 105 TCID5om1-1 vaccinia virus; 107 TCID5om1-1 vaccinia 
virus, subjected to UV-inactivation and heat-inactivation; NaCl. For 
each dilution, 0.05 ml were injected at 3 sites. 3 monkeys were treated 
daily with HLI from day -1 to day 7 at 5 x 105 units/kg-1 i.m. The HLI 
was prepared as described previously (Cantell & Hirvonen, 1978). The 
preparation used in these experiments had an activity of 2.1 x 106 
unitsjmg protein. 
RSb cells, described in chapter 2 of this thesis, or rhesus monkey 
skin fibroblasts, described in chapter 3, were plated in microtitre 
plates, grown to confluency (4 x 104 cells/well) and treated with serial 
dilutions of HLI containing 104 units/ml of rhesus monkey sera (before 
and after injection of 5 x 105 units/kg-1 HLI). After overnight incuba-
tion, the supernatant was removed and cells were infected with VSV or 
vaccinia virus (multiplicity of infection 0.25 TCID50;cell). The incu-
bation was terminated when untreated infected control cells showed more 
than 90% CPE. The cells were stained with crystal violet. Both viruses 
Fig. XVIII. In vivo effect of HLI in rhesus monkeys infected intradermaZZy with vaccinia virus. The 
vaccination sites 12 days after infection are shown in a rhesus monkey treated with HLI (left) and in 
a contPol monkey (right); (a) 10? TCID5omz-1 vaccinia viPUs; (b) 106 TCID5omz-1 vaccinia viPus; 
(c) 105 TCIDsomz-1 vaccinia virus; (d) 101 TCIDsomz-1 vaccinia virus_, subjected to UV-inactivation and 
heat inactivation~ (e) NaCZ. 
,_. 
C) 
<0 
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were always tested simultaneously in the same microtitre plate and an 
interferon standard preparation was included. The activity of inter-
feron is expressed as the reciprocal of the highest dilution giving 
50% protection. The titres are given as reference units (tested against 
standard preparation 69/19 of the Medical Research Council). 
Results and Discussion 
In control monkeys the lesions reached their maximum on day 7. Daily 
i.m. injections of 5 x 105 units HLI/kg body weight during 8 days com-
pletely inhibited the development of the typical vaccinia-induced skin 
lesions (Fig. XVIII). No skin lesions were detected during the obser-
vation period of 4 weeks following infections. However, we were unable 
to correlate this distinct in vivo effect of HLI with a corresponding 
inhibition of the CPE of the same virus on diploid rhesus monkey skin 
fibroblasts or on RSb cells. Up to 104 units of HLI failed to protect 
the cells against the CPE of vaccinia virus (RIV strain), although the 
CPE of VSV was effectively i nhi bi ted (Tab 1 e 30). 
Table 30. In vitro inhibition of the CPE of vaeeinia virus by HLI 
and serum fPom treated rhesus monkeys 
Preparation RSb cells Skin fibroblasts from 
rhesus monkeys 
VSV Vaccinia vsv vaccinia 
virus virus 
HLI, 104 uni ts/ml-1 10,000 < 1 10,000 < 1 
Pre-serumt < 10~ <10 nd~ nd 
Post-serumt 350~ <10 nd nd 
t Before and after 4 h after injection of rhesus monkeys with 
5 x 105 units/kg HLI ! Mean titre of 3 monkeys 
nd = not determined 
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Surprisingly, vaccinia virus was resistant to interferon in our in 
vitro system, but the same results were obtained in vitro with the 
vaccinia virus strain WR and with smaller challenge doses (10-3 TCI050 ; 
this thesis, chapter 3). Also no anti-vaccinia activity could be de-
tected in the sera of the monkeys 4 h after the first injection with 
HLI. At this time, the sera showed the maximum titre of antiviral acti-
vity when tested against VSV. Similar experiments performed with human 
diploid skin fibroblasts and rhesus monkey kidney cells showed identi-
cal results. There was also no inhibition of the production of infect-
ious vaccinia virus. 
These findings indicate that interferon can be effective in vivo 
against a virus which is insensitive to its antiviral action in various 
cell types. Likewise, it has been shown by others (Gresser et al.1972) 
that interferon can inhibit in vivo the growth of tumour cells which 
are resistant to its growth inhibitory action in vitro. Interferon may 
activate several defence systems of the host, for example, the cyto-
toxicity of the NK cells and the macrophages (Gidlund et al. 1978; 
Gresser & Tovey, 1978). Perhaps such 'aggressive' cells can selectively 
destroy virus-infected cells in vivo. 
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SUMMARY 
This thesis describes our three-year wandering through the interferon 
field from 1976 to 1979. It is introduced by a chapter (1) reviewing 
the present state of knowledge of the interferon system. The next three 
chapters (2, 3 and 4) are concerned with production, antiviral activity 
and cell growth inhibition of interferon in vitro. Thereafter, we pre-
sent in chapters 5, 6 and 7 our in vivo studies on human interferon ad-
ministration in therapeutic and prophylactic settings. 
In chapter 2 we describe the production of rat interferon of rela-
tively high activity (about 106 units(mg protein) in embryonic rat 
cells treated with Newcastle disease virus at a high multiplicity of 
infection. The cells were cultured in serum-free medium and the inter-
feron was precipitated and concentrated with 0.02 M-zinc acetate or 
with ammonium sulphate with 85% saturation. With both methods the 
increase in interferon activity was greater than the concentration 
factor. The rat interferon activity was stable on treatment with 0.15 
M-perchloric acid and after 3 cycles of freezing and thawing, but incu-
bation at 37° C for 1 h resulted in a 50% loss in activity. It had no 
cross activity in human or mouse cells. The sensitivity of different 
types of rat cells for interferon differed widely and was dependent on 
the challenge virus. Human interferons had no detectable antiviral ac-
tivity on rat cells and did not block the activity of rat interferon. 
In chapter 3 the dependence of antiviral activity of interferon on 
multiplicity of infection (MOl) is shown. Cells could not be protected 
against the cytopathogenic effect of vaccinia, herpes, ECHO or vesicu-
lar stomatitis virus at an MOl > 1. At an MOl ~ 1, cells could be pro-
tected. The amount of protecting interferon was inversely related to 
the MOl. When protection was afforded, it was only transient. The dura-
tion of the antiviral effect of interferon was also inversely related 
to the MOl. 
The dependence of the antiviral effect on the MOl could not be ex-
plained by assuming the viruses to be mixtures of subtypes with diffe-
rent interferon sensitivity. Also selection by interferon treatment of 
interferon-insensitive subtypes could not be shown. The greater anti-
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viral effect of interferon at low MOl was not caused by induction of 
interferon by the infecting virus. A direct inactivation by the virus 
of the antiviral effect of interferon could not be demonstrated. These 
results indicate that when interferon-treated cells are infected, they 
will not survive the infection. The only result of the interferon 
treatment will be inhibition of viral replication, to some extent lea-
ding only to a delay in cell death. 
Chapter 4 contains 2 studies on the inhibition of cell multiplication 
by interferon. The first part describes a study of the toxicity of 
interferon to bone marrow by the use of in vitro colony-forming assays 
for haemopoietic cells. The relative inhibitory effects of 2 interferon 
preparations, HLI and HFI, were compared with regard to their effect on 
both myeloid (CFUc) and erythroid {CFUe) progenitor cells. CFUe forma-
tion in human bone marrow cells in vitro appeared to be fairly resis-
tant to both interferons. Only high doses of both interferons gave a 
marked inhibition of CFUe. However, the toxicity of HL! and HFI was 
divergent for CFUc formation in bone marrow. HLI appeared to be consi-
derably more inhibitory for CFUc than HFI. The effects of mouse inter-
feron, induced in L929 cells, on the growth of CFUc and CFUe in murine 
bone marrow cells were comparable with those of HFI on human cells. 
The toxicity of human and murine interferons was species-specific. 
Except for the toxicity of HLI to CFUc in human bone marrow, the toxi-
city of interferon was marked only with concentrations of interferon far 
exceeding the amount necessary to produce an antiviral state in vitro. 
In the second part of chapter 4, the cell growth inhibition of inter-
feron during conditions of viral inflammation is described. This anti-
cellular activity was not affected by viral challenge nor by simulta-
neous treatment of cells with different types of interferon. Elevated 
temperatures enhanced the cell growth inhibitory activity of both HL! 
and HFI. Cell growth inhibition was measured by a dye uptake and elu-
tion technique. Results with this technique were similar to those ob-
tained by cell counting and measurement of 3H-TdR incorporation. 
In chapter 5 we present 3 studies on the effects of HF! and HL! in 
chronic HBsAg positive hepatitis. HFI had no effect on hepatitis B 
virus indices, while HLI induced a fall in HBc-associated DNA polyme-
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rase activity, This enzyme activity is supposed to reflect the number 
of circulating full Dane particles (the proposed hepatitis B virus). 
In a double-blind long-term study with high doses of HLI we found no 
effect of interferon on other indices of hepatitis B virus than DNA 
polymerase activity. The fall in DNA polymerase activity can readily 
be explained by fever that was associated with HLI administration. 
In our opinion, treatment of chronic HBsAg-positive hepatitis with 
interferon alone has no beneficial effect. 
In chapter 6 we report our data on a double-blind study of HFI 
administration in renal transplant recipients. Because interferon is 
especially effective in animal models when given prophylactically, 
human interferon preparations can be expected to be useful when acute 
viral infections can be predicted. This occurs after renal allograft 
transplantation. However, intramuscular administration of 3 x 106 units 
HFI given twice weekly for 3 months did not control viral infections. 
In view of these results we developed a primate model in an attempt to 
find an effective dosage schedule for human interferon administration. 
In chapter 7 we describe an experimental vaccinia virus infection in 
rhesus monkeys and the prophylactic antiviral activity of systemically 
administered human interferon. Daily injections of HLI (5 x 105 units/ 
kg) given from day -1 to day 7 after vaccination protected the monkeys 
completely against vaccinia virus. No skin lesions developed after dis-
continuation of therapy. Lower dosages decreased the severity of these 
lesions. Intramuscular gifts of 5 x 105 reference units/kg of HFI re-
sulted in similar serum levels and were equally effective in reducing 
skin lesion score as 1.25 x 105 reference units/kg HLI. 
We showed that systemically administered human interferon prepara-
tions had an antiviral activity in vivo against vaccinia virus. However, 
vaccinia virus proved to be resistant to these interferon preparations 
in our in vitro systems. Also no anti-vaccinia activity could be detect-
ed in the sera of the monkeys 3 to 4 h after the first interferon in-
jection. These findings indicate that interferon can be effective in 
vivo against a virus that is insensitive to its antiviral action in 
vitro. We concluded that the antiviral effect of interferon in vivo may 
be mediated by the host. 
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SAMENVATTING (SUMMARY IN DUTCH) 
In dit proefschrift worden enkele aspecten van het interferon systeem 
beschreven, waaraan wij van 1976 tot 1979 gewerkt hebben. 
Hoofdstuk 1 geeft een overzicht van de huidige kennis over inter-
feron. Hoofdstukken 2, 3 en 4 handelen over productie, antivirale ac-
tiviteit en celgroeiremming in vitro. In de hoofdstukken 5, 6 en 7 
komen de in vivo studies aan de orde, waarin humaan interferon thera-
peutisch en profylactisch werd toegediend. 
In hoofdstuk 2 wordt een methode beschreven om op grote schaal ratte-
interferon te produceren met Newcastle disease virus als inductor. Er 
kon gebruik worden gemaakt van serum-vrij medium, waardoor slechts een 
zuiverings- en concentratieprocedure nodig was om interferon van hoge 
activiteit te verkrijgen. Na precipitatie en concentratie met 0.02 M-
zink acetaat of met 85% verzadigd ammonium sulfaat bleek de interferon 
activiteit boven de concentratiefactor toe te nemen. Ratte-interferon 
was bestand tegen 0.15 M-perchloorzuur en tegen driemaal invriezen en 
ontcooien. Incubatie bij 37° C gedurende een uur resulteerde in een 
50% verlies van activiteit. De gevoeligheid voor interferon van ver-
schillende typen rattecellen bleek sterk te varieren en was bovendien 
virus-afhankelijk. Ratte-interferon was niet actief in menselijke en 
muizecellen. Humane interferonen toonden geen antivirale activiteit in 
rattecellen en konden de activiteit van ratte-interferon op die cellen 
niet blokkeren. Wij concludeerden dat het ratte-interferonsysteem niet 
verschilt van dat van andere species. 
In hoofdstuk 3 wordt aangetoond dat de antivirale activiteit van 
interferon afhankelijk is van de hoeveelheid infecterend virus (multi-
plicity of infection, MOl). Cellen konden door interferon niet worden 
beschermd tegen vaccinia, herpes, ECHO en vesicular stomatitis virus 
wanneer de 1401 > 1 was. Bij een MOl _:: 1 werd wel bescherming gevonden. 
De hiervoor benodigde hoeveelheid interferon was omgekeerd afhankelijk 
van de MOl. Bescherming bleek een tijdelijk fenomeen te zijn: hoe hager 
de MOl was, des te korter de bescherming aanhield. Verschillende moge-
lijkheden werden nagegaan om de MOl afhankelijkheid van interferon te 
verklaren. Uitgesloten werd dat dit verschijnsel wordt veroorzaakt door 
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de aanwezigheid van subtypen virussen met verschillende interferon ge-
voeligheden. Oak werd geen selectie van interferon ongevoelige sub-
typen gevonden door interferon behandeling. Het antivirale effect van 
interferon bij lage MOl werd niet veroorzaakt door inductie van inter-
feron door het infecterende virus. Evenmin werd directe inactivatie 
van het antivirale effect van interferon door virus gevonden. Wij con-
cludeerden dat oak met interferon behandelde cellen een virale infectie 
niet kunnen overleven. Door interferon wordt de virale replicatie 
slechts geremd, zodat celdood wordt uitgesteld. 
Hoofdstuk 4 bevat twee studies over de celgroei-remmende werking van 
interferon. In het eerste gedeelte werd dit effect bestudeerd met 
behulp van beenmergkweken in agar. De remmende werking van humaan leu-
cocyten interferon (HLI) en humaan fibroblasten interferon (HFI) op 
voorlopercellen van de myelo1de (CFUc) en erythroide (CFUe) reeks 
werden met elkaar vergeleken. Interferon bleek CFUe formatie nauwelijks 
te beinvloeden. HLI remde CFUc vorming veel sterker dan HFI. Muize-
interferon, ge1nduceerd in Lg29 cellen, remde de groei van CFUc enCFUe 
in muizebeenmerg op dezelfde wijze als HFI dit in menselijke cellen 
deed. Celgroeiremming van de onderzochte interferonen was species-
specifiek. 
In het tweede gedeelte van hoofdstuk 4 werd de celgroeiremmende 
eigenschap van interferon onderzocht onder omstandigheden van een vira-
le infectie. Het anticellulaire effect werd niet be1nvloed door virus, 
noch door het tegelijk aanwezig zijn van verschillende typen interferon. 
Hogere temperaturen (38-39° C) deden de cytotoxiciteit van zowel HLI 
als HFI toenemen. De groei van cellen in monolayer werd gemeten meteen 
kleur- en extractiemethode. Resultaten met deze snelle techniek bleken 
identiek te zijn aan die verkregen met celtelling en met de bepaling 
van 3H-TdR incorporatie. 
In hoofdstuk 5 komen onze pogingen aan de orde om chronische HBsAg 
positieve hepatitis therapeutisch te beinvloeden met interferon. HFI 
had geen effect op hepatitis 8 virus indices, terwijl HLI een daling 
van de HBc-'associated' DNA polymerase (DNAP)-activiteit veroorzaakte. 
Deze enzymactiviteit is een maat voor de hoeveelheid circulerende Dane 
partikels (het veronderstelde hepatitis B virus). 
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In een dubbelblinde studie met hoge doses HLI vonden wij echter geen 
ander effect op hepatitis 8 virus indices dan de al genoemde daling van 
het DNAP. Deze daling zou het gevolg kunnen zijn van de door HLI gein-
duceerde koorts en hoeft niet te berusten op replicatieremming van het 
hepatitis B virus. Naar ons inzicht is toediening van uitsluitend in-
terferon aan patienten met chronische HBsAg positieve hepatitis niet 
zinvol. 
In hoofdstuk 6 wordt een dubbelblinde studie met p-• in niertrans-
plantatiepatienten beschreven. In dierexperimenteel werk komt de anti-
virale activiteit van interferon voornamelijk tot uiting wanneer het 
profylactisch wordt toegepast. Daarom kan men veronderstellen dat men-
selijke interferonpreparaten klinisch waardevol zullen zijn in die 
situatie, waar men virale infecties kan verwachten. Dit is het geval 
na niertransplantaties. Intramusculaire toediening van 3 x 106 units 
HFI tweemaal per week gedurende 3 maanden was echter niet in staat 
virale infecties bij niertransplantatiepatienten te voorkomen. Om deze 
reden ontwikkelden wij een primatenmodel ten einde tot een effectief 
antiviraal doseringsschema voor humaan interferon te komen. 
In hoofdstuk 7 wordt een experimentele vaccinia virus infectie in de 
rhesusaap beschreven. Dagelijkse injecties van 5 x 105 units/kg HLI van 
dag -1 tot dag 7 na vaccinatie beschermden de apen volledig tegen 
vaccinia virus. Er ontstonden ook geen huidlaesies na dag 7. Lagere 
doses HL! verminderden de ernst van deze huidlaesies. Intramusculaire 
toediening van 5 x 105 units/kg HFI resulteerde in gelijke bloedspie-
gels en was ook even effectief als 1.25 x 105 units/kg HLI. 
Systemisch toegediend humaan interferon kon dus een antivirale ac-
tiviteit in vivo uitoefenen, in dit geval bij vaccinia virus. Het bleek 
echter dat vaccinia vi russen resistent waren tegen interferon in vitro. 
In de sera van de apen was ook geen anti-vaccinia activiteit aantoon-
baar 3-4 uur na toediening van interferon. Interferon kan dus in vivo 
effectief zijn tegen een virus dat ongevoelig is voor de antivirale 
werking van interferon in vitro. 
Wij concludeerden dat het antivirale effect van interferon in vivo 
niet op replicatieremming van het virus hoeft te berusten maar via 
gastheermechanismen kan verlopen. 
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ALT 
AST 
CAH 
CF test 
CFUc 
CFUe 
CMV 
CPE 
cpm 
DEAE 
DMEM 
DMSO 
DNA 
DNAP 
ORB 
ds-RNA 
EBV 
ELISA 
FCS 
HBcAg 
HBeAg 
HBsAg 
HEL cells 
HE PES 
HFI 
HI test 
HLI 
HSV 
i.m. 
i. v. 
MIF 
r~oi 
MOPS 
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LIST OF ABBREVIATIONS 
alanine aminotransferase 
amino aspartate transferase 
chronic active hepatitis 
complement fixation test 
human myeloid .colonies (colony forming units) 
human erythroid colonies (colony forming units) 
cytomegalo virus 
cytopathogenic effect 
counts per minute 
diethylaminoethyl 
Dulbecco's modification of Eagle's minimal essential medium 
dimethylsulphoxide 
deoxyribonucleic acid 
DNA polymerase 
dichloro-1-S-D-ribofuranosyl benzimidazole 
double-stranded RNA 
Epstein-Barr virus 
enzyme-linked immunosorbent assay 
foetal calf serum 
hepatitis B core antigen 
hepatitis B 'e' antigen 
hepatitis B surface antigen 
human embryo lung cells 
hydroxyethylpiperazine-N'-2-ethane sulphonic acid 
human fibroblast interferon 
haemagglutination inhibition test 
human leucocyte interferon 
herpes simplex virus 
intramuscular(ly) 
intravenous (ly) 
mouse interferon 
multiplicity of infection 
morpholinopropane sulphonic acid 
NCS 
nd 
NOV 
NK cell 
PBS 
PFU 
P/N ratio 
poly(rl). 
poly(rC) 
REC 
RIF 
RIV 
RM cells 
RNA 
ROS cells 
RSb cells 
RSC cells 
RSV 
RUC cells 
SD 
TCIDSO 
TES 
u 
VS 
vsv 
vzv 
XC cells 
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newborn calf serum 
not done (determined) 
Newcastle disease virus 
natural killer cell 
phosphate buffered saline 
plaque forming units 
positive/negative ratio 
polyinosinic-polycytidylic acid 
rat embryo cells 
rat interferon 
Rijksinstituut voor de Volksgezondheid 
cells derived from a spontaneous rat rhabdomyosarcoma 
ribonucleic acid 
cells from a rat osteosarcoma 
Rous sarcoma virus-transformed human cells 
cells from a radiation-induced rat skin carcinoma 
respiratory syncytial virus 
cells from rat urethral carcinomas 
standard deviation 
tissue culture infective dose (50%) 
tris-(hydroxymethyl)methyl-2-aminoethane sulphonic acid 
units 
versus 
vesicular stomatitis virus 
varicella zoster virus 
cells derived from a Rous sarcoma virus-induced rat tumour 
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